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ABSTRACT 
 
 
Mullins, Jeremi Stevan.  M.S., Department of Biological Sciences, Wright State 
University, 2008.  Immunomodulation of human skin cells by extracts of the scabies 
mite, Sarcoptes scabiei.   
 
 
 
 Sarcoptes scabiei infests its host through burrowing into the stratum corneum 
layer of skin.  Keratinocytes and fibroblasts responding to the burrowing mite(s) and/or 
mite products produce inflammatory and immune activating cytokines and chemokines.  
The purpose of this study was to determine if an extract of S. scabiei can modulate 
cytokine and chemokine expression from keratinocytes and fibroblasts in vitro.  Normal 
human keratinocytes and fibroblasts were exposed to an extract of S. scabiei var. canis 
with or without various pro-inflammatory stimuli.  Cytokine and chemokine expression 
were measured by enzyme-linked immunosorbent assay (ELISA).  Scabies extract 
increased expression of interleukin-6 (IL-6), growth-related oncogene-α (GRO-α), 
transforming growth factor-α (TGF-α), and cutaneous T-cell attracting chemokine 
(CTACK) by keratinocytes.  In contrast, scabies extract decreased expression of 
interleukin-8 (IL-8) by keratinocytes.  In comparison, scabies extract increased 
expression of IL-6 and granulocyte-colony stimulating factor (G-CSF) by fibroblasts.  In 
contrast, scabies extract decreased expression of granulocyte/macrophage-colony 
stimulating factor (GM-CSF) and IL-8 by fibroblasts.  These findings demonstrate that S. 
scabiei can modulate cytokine and chemokine expression by human keratinocytes and 
fibroblasts.                    
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INTRODUCTION 
Rationale for these studies 
 Human skin possesses an innate ability to protect its host from dehydration, 
allergens, and toxins through establishment of a physical barrier to the outside world.  If 
this barrier is breached and the underlying tissues are threatened, residential skin cells 
including keratinocytes, fibroblasts, and endothelial cells exhibit immune competence 
through production and expression of cell-signaling polypeptides called cytokines and 
chemokines.  These non-leukocyte derived cytokines and chemokines activate and recruit 
various leukocyte sub-populations such as lymphocytes, monocytes, and granulocytes to 
areas of tissue injury and inflammation.  Thus, nonhematopoietically-derived skin cells 
are important in initiating and sustaining inflammatory and immune responses at site 
specific locations within skin.  This is accomplished through cytokine and chemokine 
“crosstalk” with bone-marrow derived cells that control and clear any invading 
environmental threat.  Therefore, any modulation in cytokine and/or chemokine 
expression by residential sessile cells of the skin in response to various external stimuli 
allows for a mechanistic approach to investigate and delineate cellular communication 
occurring within the cutaneous microenvironment.   
Studies between keratinocytes and fibroblasts have shown that fibroblasts, upon 
signal-induced activation from primary keratinocyte-derived cytokines including IL-1α 
and TNF-α, produce significant quantities of secondary cytokines such as interleukin-6, 
and -8 (Boxman et al., 1993; Waelti et al., 1992; Arlian et al., 2003; Kupper et al., 1990).  
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Interleukin-6 (IL-6) has been described to promote T-cell differentiation (TH1/TH2) and 
B-cell immunoglobulin secretion and interleukin-8 (IL-8) induces chemotaxis of 
neutrophils, basophils, and various leukocyte subsets while contributing significantly to 
angiogenesis (Koch et al., 1992).   Fibroblast-derived cytokines can bind to recognized 
cell-surface receptors on various effector cells, including keratinocytes and endothelial 
cells to induce further cytokine and chemokine production.  Thus, an amplification loop 
of cytokine and chemokine production occurs within the skin to initiate and sustain both 
protective and non-protective immune responses.  Determining which type of immune 
response occurs to potential threats is thus inclusive of which cytokines and chemokines 
are being produced and modulated by residential skin cells.   
 Stimulation of epithelial keratinocytes through pattern recognition receptors on 
the surface of the keratinocytes by pathogenic microorganisms, superficial fungal 
pathogens, toxic chemicals, trauma, ultraviolet irradiation, and/or parasitic allergens from 
mites and insects such as chiggers, lice, fleas, ticks, and bedbugs can result in both 
cytokine and chemokine up-regulation and down-regulation (Fallon et al., 1996; Shiraki 
et al., 2006; Busvine, 1977; Ramachandra and Wikel, 1992).  The response of 
keratinocytes and, in turn, fibroblasts to these stimuli is critical in maintaining proper 
protective immunity and preventing pathophysiologies of the skin commonly associated 
with such skin diseases as psoriasis, eczema, pediculosis, and/or atopic dermatitis.  
Modulation of appropriate cytokine and chemokine responses in the skin to various 
stimuli can thus inhibit or delay both innate and adaptive immune responses necessary for 
host protection.      
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Cytokine and chemokine production and modulation from keratinocytes and 
fibroblasts has also been described in association with the skin disease scabies (Arlian et 
al., 2003; Arlian et al., 1996).  Sarcoptes scabiei is a ubiquitous obligate-ectoparasitic 
arthropod that burrows deep into the corneal layer of the stratum corneum of human skin 
and other mammalian species (Arlian et al., 1995; Arlian et al., 1988c).  After a delayed 
immune response of approximately four-to-six weeks after initial infestation (Arlian et 
al., 2006a, b), symptoms including cutaneous inflammation and pruritus (intense itching) 
associated with the scabietic lesions begin to develop (Arlian et al., 2003).  The 
mechanism(s) behind this 4-6 week delayed primary immune response is not well 
understood. However, the function of normal human skin cells including monocytes, 
dendritic cells, residential lymphocytes, keratinocytes, fibroblasts, and endothelial cells 
have all been shown to be modulated by direct contact with products in an extract made 
from scabies bodies (Arlian et al., 2003, 2004a, 2006b).  A recent study to investigate a 
potential mechanism behind this delayed immune response has focused on human 
microvascular endothelial cells (HMVEC-D) and their adhesion molecules, chemokine 
receptors, and cytokine responses to an extract of S. scabiei var. canis (Arlian et al., 
2006b).  Results from this study found that S. scabiei var. canis extract inhibited 
HMVEC-D expression of E-selectin, VCAM-1, and IL-8 but increased expression of 
chemokine receptor CXCR-1 (Arlian et al., 2006b).  Likewise, a study to measure the 
potential regulatory effects of S. scabiei var. canis extract on human T-lymphocytes has 
shown that T-cells down-regulate expression of IL-4, essential in TH2 responses, and up-
regulate expression of IL-10 and IFN-γ (Arlian et al., 2006a).  It is suggested that this up-
regulation of anti-inflammatory IL-10 is by type 1 T-regulatory cells (Treg) activated by 
4 
 
molecules in the scabies extract (Arlian et al., 2006a) which may, in part, account for the 
delayed immune/inflammation response in the host.   
 Human skin equivalent models (HSEs) consisting of an epidermis of 
keratinocytes grown over a fibroblast-containing collagen matrix provided the first in 
vitro evidence that either keratinocytes, fibroblasts, or both produce and release IL-1α/β 
in response to infestation of scabies mites (Arlian et al., 1996).   Cultured keratinocytes 
and fibroblasts from non-living tissue produced morphologically and biochemically 
representative models of human skin which subsequently were infested with scabies 
mites with harvested media supernatant being assayed for IL-1α/β (Harriger et al., 1992, 
Arlian et al., 1996).  Secretion of both pro-inflammatory IL-1α/β is significant because 
these cytokines induce responses from various skin-associated immune cells including 
Langerhans cells, macrophages, monocytes, neutrophils, T and B cells, and natural killer 
cells (Dinarello et al., 1991, 1992).  IL-1 cytokines also significantly contribute to the 
differentiation of CD4+ T-helper cells into either the Th1 or Th2 subsets (Dinarello et al., 
1991, 1992).            
In a separate but similar study, monocultures of adult keratinocytes and 
fibroblasts obtained from living breast tissue were individually exposed to various 
concentrations of whole body homogenate extracts of S. scabiei var. canis and assayed 
for dose-dependent cytokine production (Arlian et al., 2003).  Scabies extract induced 
quantifiable increases in interleukin-6 and vascular endothelial growth factor (VEGF) 
with only a relatively small, but significant, increase of IL-1β from normal human adult 
keratinocytes.  Fibroblasts responded in a similar manner by up-regulating both IL-6 and 
VEGF, but showed no expression of either IL-1α/β.  The up-regulation of pro-
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inflammatory IL-6 shows significance in that IL-6 can act as a growth factor for 
keratinocytes (Grossman et al., 1989) while increasing vascular permeability from 
microvascular endothelial cells (Arlian et al., 2003), and even activating CD4+ T-helper 
cells to secrete cytokines involved in their proliferation and differentiation including 
interleukin-2 and -4 (Arlian et al., 2003).  The importance in the up-regulation of VEGF 
in this study is also apparent due to this cytokines’ ability to increase vascular 
permeability of microvascular endothelial cells and induce inflammation (Liekens et al., 
2001; Dvorak et al., 1995) during scabies infestation.  Ironically, up-regulating VEGF 
(expressed in this study by both keratinocytes and fibroblasts) may prove beneficial to the 
survival of the parasite by substantially increasing perivascular fluid into the site of 
infestation thus conferring upon the mite proper nutrition and water balance (Arlian et al., 
1988a).  In this study adult keratinocytes also down-regulated secretion of interleukin-1 
receptor antagonist (IL-1ra) and interleukin-8 (IL-8) in response to scabies extract (Arlian 
et al., 2003).  IL-1ra has shown significance in the inflammation control process by 
competitively binding IL-1α/β to the IL-1 receptors found on T-cells, B-cells, natural 
killer cells, vascular endothelial cells, macrophages, neutrophils, keratinocytes, and 
fibroblasts (Kupper et al., 1995; Haskill et al., 1991; Dvorak et al., 1995; Bigler et al., 
1992).  Overall, these studies provide insight into a potential mechanism behind the 
delayed immune and inflammatory responses occurring during initial scabies infestation 
and have contributed significantly to the understanding of this specific host-parasite 
relationship.               
Additional research is required to further understand which cytokines and 
chemokines can be modulated from residential skin cells in vitro by molecules in an 
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extract of Sarcoptes scabiei var. canis.  In this study, the primary focus will be on 
investigating the expression and modulation of previously unexplored cytokines and 
chemokines from normal human epidermal keratinocytes obtained from both neonatal 
and adult donors along with normal human dermal fibroblasts upon exposure to scabies 
extract.  In addition, a cysteine protease inhibitor called cystatin A which is a major 
component of human sweat will be investigated for its potential to augment the cytokine 
and chemokine altering capabilities from antigenic molecules found within scabies 
extract.  In a study to determine the effect cystatin A has on neonatal keratinocytes 
stimulated with two major dust mite allergens Der p 1 and Der f 1, it was discovered that 
cystatin A inhibited the IL-8 inducing effects these two allergens had on keratinocytes 
(Kato, et al., 2005).  In the epithelial barrier of skin, expression of protease inhibitors thus  
controls the potential damaging effects of inflammation associated with keratinocytes 
when they contact major allergens such as Der p 1 and Der f 1.   Since scabies mites 
share similar allergenic molecules with house dust mites, it is possible that cystatin A 
may modulate the cytokine and chemokine response of keratinocytes when exposed to 
scabies extract.    
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Role of Keratinocytes in Initiating Skin Immunity and Inflammation 
It has been suggested that the most compelling reason skin acts as an immune 
organ is due to the extensive repertoire of cytokines produced by keratinocytes (Williams 
and Kupper., 1996).  Cytokines are low molecular weight (usually 30kDa or less) 
regulatory peptides capable of being produced by virtually every cell type in the body.  
Cytokines possess pleiotropic regulatory effects on hematopoietic and many other cell 
types in the body directly involved in host defense and repair processes.  Most cytokines 
are not constitutively expressed; however their expression is regulated by various 
inducing stimuli at either transcriptional or post-transcriptional levels.  Keratinocytes can 
respond to exogenous and endogenous stimuli by producing of a broad spectrum of 
molecules including proinflammatory and immunomodulatory cytokines and 
chemokines, various innate effector peptides including β-defensins and cystatins, as well 
as colony-stimulating growth factors (Shiraki et al., 2006).  Proinflammatory cytokines 
derived from keratinocytes containing attributes of pleiotropy and synergism include IL-
1α, IL-1β, TNF-α, and IL-6 (Arlian et al., 2003; Shiraki et al., 2006).  Likewise, studies 
to demonstrate chemotaxis of neutrophils, eosinophils, macrophages, and Th2-
lympocytes into the skin have shown increased expression levels of keratinocyte-derived 
chemokines including IL-8, MCP-1, Eotaxin, and Eotaxin-2 (Shiraki et al., 2006).  
Immunomodulatory cytokines produced by keratinocytes which may have a predominant 
role in inducing the cell-mediated immune response include IL-7, IL-15, IL-16, and IP-10 
(Shiraki et al., 2006).  Keratinocyte secreted G-CSF and GM-CSF exhibit paracrine 
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effects by stimulating endothelial cell proliferation and migration (Bussolino et al., 
1991), while simultaneously expressing autocrine effects by stimulating growth and 
differentiation of keratinocytes (Olaniran et al., 1995).  The production of human β-
defensins stimulates keratinocytes in an autocrine manner to undergo cell proliferation, 
migration, and production of inflammatory cytokines/chemokines (Niyonsaba et al., 
2007), while cystatin molecules inactive proteases in the skin that can lead to excessive 
inflammation (Kato et al., 2005).   
Secondary Roles of Dermal Fibroblasts and Microvascular Endothelial Cells 
 Residing within the dermal layers of skin are mesenchyme-derived stromal cells 
called fibroblasts.  Fibroblasts respond to primary keratinocyte-derived cytokines, such as 
IL-1α/β and TNF-α, through receptor binding thereby initiating signal transduction and 
subsequent production of secondary cytokines.  Interleukin-6 and keratinocyte growth 
factor (KFG) are members of these secondary cytokines and play a critical role in 
stimulating keratinocyte proliferation (Werner et al., 1992; Boxman et al., 1993).  The 
recruitment of fibroblasts into the cytokine cascade by keratinocyte-derived cytokines 
thus has a positive amplification effect on cytokine production and immune/inflammation 
responses to a variety of stimuli.  Along with fibroblasts, cells constituting post-capillary 
venules called microvascular endothelial cells are found in the dermal layers.  These cells 
play crucial roles in the recruitment and extravasation of various leukocytes into the site 
of infection thus regulating specific immune and inflammatory responses.  Certain 
cytokines expressed by endothelial cells involved in this process of recruitment include 
intercellular adhesion molecule (ICAM)-1, and -2, vascular cell adhesion molecule 
(VCAM)-1, and -2, E-selectin, P-selectin, IL-8, and MCP-1.  Chemokine and cytokine 
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receptors found on endothelial cells respond to a plethora of cytokines released by both 
epidermal keratinocytes and dermal fibroblasts upon signal activation, which in turn 
regulate cell trafficking to the site of infection.  Thus, in can be determined that 
endothelial cells play at least some part in the clinical manifestations of scabies 
infestation through the active regulation of specific cytokines, chemokines, and cell-
surface adhesion molecules. 
Sarcoptes scabiei 
 Scabies is a worldwide contagious ectoparasitic disease caused by Sarcoptes 
scabiei var. hominis.  Sarcoptes scabiei derives its name from the Greek words “sarx” 
(flesh) and “koptein” (to smite or to cut) and the Latin word “scabere” (to scratch).   
Female scabies mites infest their host by burrowing into the lower levels of the intact 
stratum corneum layer of skin near the stratum corneum/stratum lucidum interface 
forming burrows along their way (Arlian et al., 1989; Estes et al., 1983, 1984).  It is in 
these burrows, or “molting pouches”, where the female mites begin to lay approximately 
three eggs per day (Arlian et al., 1989).  Larvae from these eggs hatch in approximately 
2-4 days and subsequently molt into essential developmental stages until reaching mature 
adulthood at an average of 5-6 days.  With full adult development usually occurring no 
more than 10-14 days, the scabies mite will spend its entire life cycle on humans.  The 
size of a scabies mite ranges from 0.4mm long and 0.3mm wide for the typical female, 
with the males being sufficiently smaller (Arlian et al., 1989).  Scabies mites cannot fly 
or jump, but they have been shown to crawl at a rate of 2.5cm/min on warm skin (Arlian 
et al., 1989).  At room temperature and average humidity, scabies mites retain their 
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ability to cause infestation and epidermal burrowing for 24 to 36 hours (Arlian, et al., 
1984).     
Prevalence of Scabies 
 It is estimated that by the end of the 20th century, there were nearly 300 million 
cases of scabies in the world (Orkin, 1995).  Initially, scabies was thought to be 
associated with poverty and lack of proper hygiene; however studies involving house-to-
house surveying techniques have shown that scabies are just as prevalent in middle to 
upper socioeconomic classes in developed countries (Arlian et al., 1988b; Gulati et al., 
1977).  The transmission of mites from one host to the next can occur through direct 
contact with an infected individual or through indirect contact with fomites that contain 
an infectious mite(s).  Scabies outbreaks can be particularly high in institutions including 
hospitals and nursing homes, as well as throughout socially disadvantaged populations.  
In a study to measure the prevalence of scabies mites in nursing homes, frequent 
changing of bed linens and good housekeeping practices, along with higher room 
temperatures resulted in decreased spreading of scabies among individuals (Arlian et al., 
1988b).   In some regions around the world, mainly Central and South America, scabies 
poses a major health concern due to a nearly 100% prevalence (Buffet and Dupin, 2003) 
and an increasing number of immunocompromised individuals.      
Host Specificity and Cross-infestivity 
Certain physiological differences among scabies mites relate to how these mites 
are, for the most part, host specific (Arlian et al., 1984).  A study to determine if S. 
scabiei (var. canis) from dogs infect: mice, rats, guinea pigs, pigs, cattle, cats, goats, and 
sheep were unsuccessful (Arlian et al., 1984), however S. scabiei (var. canis) were able 
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to be transmitted to New Zealand white laboratory rabbits.  Humans can become infested 
with strains of scabies from infested animals that they either handle or live with (Fain et 
al., 1978; Parlette et al., 1975); however these strains cause only temporary self-limiting 
infestations due to the inability of the mite to complete its life cycle.  The frequency by 
which this occurs worldwide is unknown.     
Clinical Scabies 
Human scabies infestation can be associated with typical signs and symptoms 
including pruritic, erythematous, papular, and vesicular lesions to the skin (Arlian, 1989) 
conducive of mild to severe itching.  Sites of infestation are typically located around 
soles and insteps of the feet, genitals, buttocks, and in the webbing in-between fingers 
and toes (Epstein and Orkin, 1976).  Diagnosis of the disease is typically delayed 4-8 
weeks after primary infestation and is thought to occur due to the development of 
sensitization (Arlian, 1989).  This can be demonstrated in patients infested with scabies 
for a second time in which they present signs and symptoms within 24-48 hours 
(Mellanby, 1944).  Scabies, if left untreated, will develop into heavy crusting of the skin 
resulting from hyperkeratosis (Arlian, 1989) which in humans is referred to as Norwegian 
scabies.  These crusts consist of dry and porous vacant mite burrows (Arlian et al., 1984; 
Van Neste and Lachapelle, 1981) and along with pruritus, rashes, and severe itching, 
provide the definitive diagnosis of scabies through microscopic observations (Arlian, 
1989).   
Treatment of scabies requires not only the treatment of the afflicted individual, 
but also his or her clothing and bed linens as well as subjects who have had close 
personal contact with the afflicted individual.  Essentially this includes decontaminating 
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all linens and towels that may have come in direct contact with the infected individual by 
hot water washing (60°C) and heated drying.  Infected individuals must be treated 
medically as well.  A previous standard treatment for scabies was the use of a topical 
medicine called 1% lindan lotion (organochlorine).  This lotion was relatively 
inexpensive and generally effective resulting in mite death after a 3 hour exposure 
(Landegren et al., 1979); however it proved unsafe due to its high potential for 
neurotoxicity, anemia, and toxic hepatitis (Rauch et al., 1990).  Incidences of lindane-
resistant Norwegian scabies have also been documented (Purvis and Tyring, 1991).  
Another lotion more commonly used to treat scabies infestation is 5% permethrin cream 
(Elimite).  Permethrin proves to be highly effective with minimal toxicity; however this 
lotion is the most expensive of all the topical scabicides (Roos et al., 2001) and can 
induce severe itching and burning upon application.  In addition, scabies mites are 
resistant to permethrin in many parts of the world so it is no longer an effective treatment 
for scabies infestations.  Other topical lotions include 10% crotamiton cream (Eurax) and 
10% precipitated sulfur in petroleum.  Although topical applications can be effective in 
treating scabies outbreaks, severe crusting associated with prolonged scabies infestations 
diminishes penetration of the scabicides into the skin.  This results in a prolonged 
exposure to a low dose of the scabicide, and therefore a greater chance for scabies to 
acquire resistance to the topical drug.  A potential solution to this problem is the orally 
administered drug called ivermectin.  Ivermectin has shown significant promise in 
combating scabies due to its relative effectiveness, convenience, and safety; however the 
use of ivermectin in the treatment of parasitic infections has not been approved by the 
United States Food and Drug Administration (Fawcett, 2003).  
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Host Immune Response to Scabies  
 Generally, it can be shown that symptoms of scabies infection results from 
delayed type-IV hypersensitivity towards scabies mites and mite-product antigens 
(Mellanby, 1944).  This is demonstrated by the 4-week latency period upon initial 
encounter to scabies, while re-exposure of hosts to scabies induces immune responses 
within 24 hours.  An increase in serum IgG and IgE along with peripheral eosinophilia 
might be indicative of a non-protective TH2 immune response considering that increased 
immunoglobulin levels can still be associated with increased re-infestation rates 
(Mellanby, 1944; Roberts et al., 2005).  Due to similarities between scabies and house 
dust mites, it has been hypothesized that their secretions share similar allergens.  
Immunological studies have shown these similarities through the cross-reactivity of  
antisera specific for house dust mite allergens to extracts of S. scabiei (Arlian et al., 
1991).  This is further demonstrated in sensitization experiments, where immunization 
with extracts of D. farinae and D. pteronyssinus resulted in decreased infestation to S. 
scabiei in rabbits (Arlian et al., 1995).  Studies involved in identifying specific scabies 
mite molecules involved in immunogenic responses have focused on Glutathione S-
transferases and scabies mite inactivated protease paralogues (SMIPPs).  Although not 
much information is known about these specific proteases, it has been hypothesized that 
binding of these proteases to cell surface receptors on epidermal keratinocytes may, in 
fact, inhibit inflammatory responses by the host.      
Novel Chemokines Involved in Atopic Skin Inflammation 
 The primary production of proinflammatory cytokines (IL-1α, IL-1β, TNF-α) is 
essential in initiating atopic skin inflammation upon skin barrier disruption or allergen 
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contact.  Recent evidence indicates that along with cytokines, several homeostatic and 
inflammatory chemokines are associated with an atopic dermatitis (AD) phenotype.  Of 
these chemokines; CCL11, CCL17, CCL18, CCL22, CCL26, CCL27, and CXCL1 have 
been shown to be directly correlated with disease activity.  CCL27, also known as 
CTACK, is a member of the chemokine superfamily and is produced exclusively by 
epidermal keratinocytes (Homey et al., 2002).  Although abundantly expressed under 
homeostatic conditions, CCL27 can be induced through signal activation by 
proinflammatory mediators, such as TNF-α or IL-1β (Homey et al., 2002).  CCL27 binds 
to receptor CCR10 found on vascular endothelial cells thereby facilitating leukocyte 
extravasation and skin inflammation.  A specific leukocyte recruited to the skin through 
CCL27-CCR10 mediated interactions is the CLA+ memory T cell bearing the receptor 
CCR4.  This receptor binds to an endothelial cell produced ligand called CCL17 which 
further mediates leukocyte migration from the perivascular pockets to subepidermal and 
intraepidermal locations.  Thus, it can be inferred that endothelial cell-derived CCL17 
and keratinocyte cell-derived CCL27 work cooperatively in attaining leukocyte arrest and 
diapedesis.   
Additional chemokines involved in initiating inflammation in atopic skin are 
CCL18 and CXCL1, 2, and 3 (GRO α, β, γ, respectively).  In studies to measure CCL18 
and its association with atopic dermatitis, a more than 100-fold increase in the amount of 
CCL18 mRNA was observed in lesional atopic skin than that seen for CCL17 (Pivarcsi et 
al., 2004).  In peripheral blood, CCL18 will bind to CLA+ memory T cells and induce 
recruitment of memory T cells to peripheral skin in vivo (Gunther et al., 2005).  These 
results suggest an important role in CCL18-driven processes in initiating and 
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exacerbating skin inflammation.  The chemokines CXCL1, 2, and 3 are induced by early 
proinflammatory cytokines (IL-1, TNF-α) and are secreted by various cell types 
including; endothelial cells, fibroblasts, and epithelial cells.  Collectively, these 
chemokines aid in leukocyte trafficking, recruitment, and activation associated with skin 
inflammation.  An influx of effector cytokines (IL-4, IL-13, and/or IFN-γ) released from 
recruited leukocytes in the skin periphery helps sustain a potent chemokine response.  An 
understanding of cytokine and chemokine circulation within the skin is therefore critical 
in understanding immune-evasive ectoparasitic infections.  
TSLP may Prove Essential in Allergic Inflammation 
 A novel IL-7-like cytokine, thymic stromal lymphopoietin (TSLP), has been 
described to trigger dendritic cell-mediated TH2 inflammatory responses (Liu, 2006).  
Actively produced by epidermal keratinocytes in lesions of atopic dermatitis, TSLP has 
been associated with migration and subsequent activation of Langerhans cells to the skin 
periphery (Soumelis, et al., 2002).  In addition, TSLP does not induce myeloid dendritic 
cells (mDCs) to produce the TH1-polarizing cytokine IL-12, nor the proinflammatory 
cytokines TNF-α, IL-1β, and IL-6 (Soumelis, et al., 2002).  Instead, TSLP has been 
shown to increase production of the chemokines IL-8 and Eotaxin-2, responsible for 
chemotaxis of neutrophils and eosinophils.  In one study, TSLP-activated dendritic cells 
induced proliferation of CD4+ T cells, which in turn, produced TH2 cytokines IL-4, IL-5, 
and IL-13, but not IL-10 nor IFN-γ (Soumelis, et al., 2002).  These newly formed TH2 
cells, by way of TSLP-induced dendritic cells, can thus be considered inflammatory TH2 
cells.  Although undetectable in normal skin or nonlesional skin in patients with atopic 
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dermatitis, TSLP is upregulated in acute and chronic atopic dermatitis lesions (Soumelis, 
et al., 2002) symptomatic of severe infestation to Sarcoptes scabiei.  
Interleukin-17 and its Role in Skin Immunity 
 Although the Interleukin-17 receptor is ubiquitously distributed on many cell 
types including keratinocytes and fibroblasts, IL-17 is produced primarily from CD4+ T 
lymphocytes (Fossiez et al., 1996; Yao et al., 1997).  In the skin, IL-17 can possess both 
pro-inflammatory and anti-inflammatory attributes by selectively up-regulating or down-
regulating certain cytokines and chemokines expressed by skin cells.  When exposed to 
dermal fibroblasts in vitro, IL-17 synergizes with TNF-α to induce increased expression 
of Interleukins 1, 6, and 8 (Katz et al., 2001); however, when exposed to keratinocytes in 
the presence of TNF-α, IL-17 selectively down-regulates the chemokine CCL27 (Kanda 
et al., 2005).  As a result, IL-17 may have a central role in establishing and subsequently 
monitoring the immune/inflammation response which occurs to scabies mite antigens 
within human skin.     
Skin Innate Immunity Includes Defensins and Cystatins 
 Human β-defensins are produced by epithelial tissues including the skin and 
respiratory tract.  These antimicrobial peptides can stimulate the degranulation of mast 
cells (Befus et al., 1999) as well as the production of proinflammatory cytokines and 
chemokines from human primary keratinocytes in vitro (Niyonsaba et al., 2007), 
suggesting that these molecules have a vital role in initiating innate skin immunity.  
Human β-defensin-2, an abundantly produced defensin peptide from psoriatic skin, is 
localized near the stratum corneum layer of skin (Huh et al., 2002), and as such, can 
potentially be regulated by an infestation of Sarcoptes scabiei. 
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 The cysteine protease activity of the group 1 allergens, Der p 1 and Der f 1, 
account for their role in allergic diseases such as asthma and atopic dermatitis (Kato et 
al., 2005).  Stimulation of epithelial cells with group 1 allergens induces production of 
cytokines and chemokines involved in the pathogenesis of respiratory asthma 
(Asokananthan et al., 2002).  Blockage of cysteine protease activity from group 1 
allergens reduces cytokine and chemokine production from epithelial cells (Sakata et al., 
2004), and as a result has led to an investigation as to whether blockage of cysteine 
protease activity reduces cytokine production from keratinocytes in a similar manner.  A 
study by Kato and others (2005) discovered that inhibition of cysteine protease activity 
from group 1 allergens on keratinocytes can be achieved by a skin-produced protease 
inhibitor called cystatin A.  Since house dust mites and scabies mites share similar  
allergens (Arlian et al., 1991), it is possible that regulation of cystatin A in human skin 
may modulate the immune and inflammation response to infestation with Sarcoptes 
scabiei.     
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SPECIFIC AIMS AND HYPOTHESIS 
 This research will focus on the investigation of previously unexplored skin-
secreted cytokines and chemokines from normal human epidermal keratinocytes 
(neonatal and adult-derived) and normal human dermal fibroblasts upon stimulation with 
whole-body homogenate extracts of Sarcoptes scabiei var. canis.  In addition, it will be 
investigated as to how scabies extract modulates cytokine and chemokine expression 
from keratinocytes and fibroblasts that are synergistically induced from either TNF-α, 
IL-1α, or IL-1β and cytokines derived from activated T-cells such as IL-4, IL-13, and IL-
17.  Co-stimulation of cells in vitro with dose-dependent concentrations of cytokines and 
scabies extract will provide insights into which cytokines are necessary to initiate 
immune and inflammation responses in vivo and which cytokines are directly modulated 
by scabies extract.  Current research into cytokine-mediated signal transduction has 
implicated novel cytokines and chemokines which play vital roles in establishing and 
maintaining immune responses to potential pathogenic invasion.  Of interest pertaining to 
this research will be the novel cytokine thymic stromal lymphopoietin (TSLP), along 
with the chemokines TARC (CCL17) and CTACK (CCL27).  Whether these novel 
polypeptides are produced under in vitro conditions will be investigated along with any 
expression modulation caused by molecules within scabies extract.  Also, keratinocytes 
will be assayed for their ability to produce IL-6, IL-8, IL-1ra, TGF-α and GRO-α, while 
fibroblasts will be assayed for expression of IL-6, IL-8, G-CSF and GM-CSF.   
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Based on previous results that molecules within a whole-body homogenate extract 
of Sarcoptes scabiei var. canis down-regulates IL-8 production from keratinocytes, it will 
be investigated as to whether an apparent IL-8 suppressor found within scabies extract 
can be separated out by centrifugation.  Suppression of IL-8 during scabies infestation 
may prove beneficial in decreasing the amount of neutrophil accumulation within skin 
thus allowing the parasite to reproduce and establish excessive numbers of scabies mites.        
It is my hypothesis that normal human epidermal keratinocytes, both neonatal and 
adult, along with normal human dermal fibroblasts will produce significant amounts of 
novel cytokines and chemokines upon being synergistically induced from either TNF-α, 
IL-1α or β, and/or T-cell derived cytokines such as IL-4, IL-13, or IL-17.  Under these 
conditions, scabies extract will potentially modulate the expression of these novel 
cytokines and chemokines thus providing useful information as to how scabies evades the 
initial immune response during infestation.  Finally, the cysteine protease inhibitor 
cystatin A will be investigated due to the potential that it may modulate the cytokine and 
chemokine up-regulatory or down-regulatory capabilities of SS extract by interfering 
with inactivated proteases found within whole-body homogenate extract.  Through in 
vitro representation of the potential microenvironment that scabies antigens may 
encounter within human skin, it can be determined as to how these molecules 
successfully modulate the host immune response.  Hopefully, this mechanistic approach 
will allow for novel therapeutic targets for future studies on the skin disease scabies.       
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MATERIALS AND METHODS 
 
SARCOPTES SCABIEI VAR. CANIS EXTRACT 
Scabies extract (SS) was prepared from Sarcoptes scabiei var. canis (originally 
obtained from dogs) maintained on New Zealand White Rabbits as previously described 
(Morgan and Arlian, 1994).  Although canines are the natural host for Sarcoptes scabiei 
var. canis, New Zealand White Rabbits provide a suitable host for culturing these mites 
with infestations being localized and occurring over a longer period of time (Arlian et al., 
1984).  There is no current method for culturing Sarcoptes scabiei var. hominis, the strain 
which infests and causes scabies in humans. 
Scabies (SS) extract was prepared by combining precisely 250mg frozen scabies 
mites with 5.0mL deionized water into a TenBroeck glass homogenizer.  This aqueous 
solution was covered with parafilm, vortexed, and incubated overnight at 5°C.  On the 
following day, the tube containing the aqueous solution was vortexed and the mites were 
ground using a pestle inside the TenBroeck tube.  Mite solution was poured into a clean 
15mL centrifuge tube and then centrifuged for 15 minutes at 2700rpm.  Following 
centrifugation, the supernatant was removed and placed into a clean 15mL centrifuge 
tube through the use of a Pasteur pipette.  In order to re-suspend the pellet, 2.0mL of 
deionized water was added with several minutes of both vortexing and sonicating being 
performed.  After re-suspension, the solution was poured back into the TenBroeck tube.  
An additional 2.0mL of deionized water was added to the 15mL centrifuge tube used to 
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centrifuging to rinse the tube.  This solution was also poured back into the TenBroeck 
tube for a total of 4.0mL inside the tube.  The TenBroeck tube was covered with 
parafilm, vortexed and stored at 5°C until the following day.  On the following day, the 
pestle was used to grind any remaining mites within the TenBroeck tube exactly as 
previously described.  The solution was poured into a clean 15mL centrifuge tube.  The 
TenBroeck tube was rinsed twice each time with 500μL deionized water.  This solution 
was added to the solution in the 15mL centrifuge tube.  The tube was centrifuged for 15 
minutes at 2700rpm.  The supernatant was removed as previously described and added to 
the tube containing the homogenate mite extract.  The total volume of mite supernatant 
was sterile filtered using a 0.2μm filter.   Mite extract was prepared and labeled #070416, 
#080104, and #080125 to signify the date of the procedure.  Total protein content in the 
mite extracts was determined through the Bradford protein assay (Bradford, 1976) using 
Bovine Serum Albumin as a comparative standard.   
NORMAL HUMAN EPIDERMAL KERATINOCYTES-NEONATAL AND ADULT  
Cryopreserved neonatal epidermal keratinocyte cells (NHEK-neo) and 
cryopreserved adult epidermal keratinocyte cells (NHEK-adult) and all media and growth 
factors were purchased from Cambrex Bio Science Walkersvile, Inc.  (Walkersville, 
MD).  Cells are cultured in Clonetics keratinocyte basal medium-2 supplemented with 
bovine pituitary extract (BPE), human epidermal growth factor (hEGF), insulin, 
hydrocortisone, transferrin, epinephrine, and gentamicin/amphotericin B (GA-1000) at 
37°C in 5-7% CO2.  Cell cultures were maintained in BD Falcon (Bedford, Mass., USA) 
75cm2 tissue-culture-treated flasks.  Prior to being used in cytokine and chemokine 
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detection studies, cells were allowed to reach confluency in either 24- or 48-well tissue-
culture-treated plates.     
NORMAL HUMAN DERMAL FIBROBLASTS   
Cryopreserved adult normal human dermal fibroblasts (NHDFs) and all media 
and growth factors were purchased from Cambrex Bio Science Walkersvile, Inc. 
(Walkersville, MD).  NHDFs are cultured in BD Falcon (Bedford, Mass., USA) 75cm2 
tissue-culture-treated flasks using Clonetics fibroblast basal medium-2 supplemented 
with fetal bovine serum (FBS), insulin, recombinant human fibroblast growth factor-B 
(rHFGF-B), and gentamicin/amphotericin B (GA-1000) at 37°C in 5-7% CO2.  Prior to 
being used in cytokine and chemokine detection studies, cells were allowed to reach 
confluency in 48-well tissue-culture-treated plates.   
HUMAN SKIN CELLS CHALLENGED WITH SCABIES (SS) WHOLE-BODY 
EXTRACT 
 Data obtained from preliminary experiments determined the optimum dosage and 
time course by which to challenge NHEK-neonatal and NHDF with SS extract and 
lipopolysaccharide (LPS).  Cytokine and chemokine production from these skin cells 
were measured from the cell culture supernatant via ELISA.  
Briefly, NHEK-neonatal and NHDF were seeded in individual 48-well tissue-
culture-treated plates at a cell density of ~10,000 cells/well.  Each of the two cell types 
were then allowed to grow to confluency using their respective growth mediums (KGM-2 
for keratinocytes and FGM-2 for fibroblasts).  In preparation for challenging both 
NHEK-neo and NHDF, SS extract #070416 was prepared at concentrations of 200, 100, 
50, and 25μg/mL in each cells respective growth medium.  In addition, SS extract 
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#070416 was prepared at the above concentrations with 100ng/mL lipopolysaccharide 
(LPS).  After reaching confluency, medium from each well was removed and replaced 
with 500μL of fresh-pre-warmed growth medium.  Exactly 500μL SS extract or 500μL 
SS extract + LPS was then added to each respective well according to the 48-well plate 
layout.  Since each well already contained 500μL growth medium prior to challenge, the 
final concentrations of SS extract in each well was 100, 50, 25, and 12.5μg/mL, while 
LPS was at a concentration of 50ng/mL, respectively.  Cells were challenged in triplicate 
(n=3) for each dosage of SS extract and each dosage of SS extract + LPS.  NHDF were 
challenged for 12 and 24 hours, while NHEK-neo were challenged for only 24 hours at 
37°C and 5-7% CO2.  At the end of the dosing period, approximately 1mL of supernatant 
was removed from each well according to the plate layout and stored at -80°C for ELISA 
analysis of cytokine and chemokine expression.   
HUMAN SKIN CELLS CHALLENGED WITH TNF-α AND SS EXTRACT 
 Preliminary studies were performed to determine the optimum dosage of TNF-α 
in which to stimulate the cells.  Briefly, NHEK-neonatal were seeded in two 24-well 
tissue-culture-treated plates at cell densities of ~50,000 cells/well and allowed to grow to 
confluence using KGM-2.  Upon reaching confluency, each plate was challenged with 
TNF-α at 5ng/mL along with SS whole-body homogenate extract at concentrations of 
100, 50, 25, and 12.5μg/mL for either 8 or 24 hours.  Both plates were incubated at the 
standard conditions of 37°C and 5-7% CO2.  Following the incubation periods, media 
supernatants from both plates were removed and frozen at -80°C until further cytokine 
and chemokine analysis could be performed. 
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 To determine whether an IL-8 suppressor molecule can be separated from the 
whole-body homogenate extract of scabies, a repeat of this study occurred using 
centrifuged SS extract instead of whole-body extract.  Essentially, the exact same 
protocol as was just described for whole-body homogenate extract was used except the 
extract was first centrifuged for 10 minutes at 14,500 rpm.  Upon centrifugation, two 
distinct layers of SS extract were observed.  Each distinct layer (supernatant and pellet) 
was then added to a volume of KGM-2 and subsequently used to stimulate the cells.  For 
each layer, two 24-well tissue-culture-treated plates of NHEK-neonatal were used at 8 
and 24 hours.  Plates were incubated accordingly at 37°C and 5-7% CO2.  After the 
appropriate incubation times, the media supernatants were removed and stored at -80°C 
for ELISA analysis of cytokine and chemokine expression.   
HUMAN SKIN CELLS CHALLENGED WITH TNF-α, IL-17, AND SS EXTRACT 
 Preliminary studies were performed to determine the optimum dosage of TNF-α 
and IL-17 in which to synergistically stimulate the cells.  Briefly, NHEK-adult were 
seeded into a 24-well tissue-culture-treated plate at a cell density of ~50,000 cells/well 
and grown to confluence using KGM-2.  NHEK-adult were challenged with either TNF-
α at 5ng/mL, IL-17 at 10ng/mL, or TNF-α at 5ng/mL and IL-17 at 10ng/mL.  In addition, 
wells containing both TNF-α and IL-17 were challenged with SS whole-body 
homogenate extract at concentrations of 100, 50, 25, and 12.5μg/mL.  The 24-well plate 
was incubated for 24 hours at 37°C and 5-7% CO2.  After 24 hours, supernatants were 
removed and frozen at -80°C for ELISA analysis of cytokine and chemokine expression.    
 Likewise, NHDF were seeded into a 48-well tissue-culture-treated plate at a 
density of ~10,000cells/well and grown to confluence using FGM-2.  NHDF were also 
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challenged with either TNF-α at 5ng/mL, IL-17 at 10ng/mL, or TNF-α at 5ng/mL and 
IL-17 at 10ng/mL.  Wells containing both TNF-α and IL-17 were also challenged with 
SS whole-body homogenate extract at concentrations of 100, 50, 25, and 12.5μg/mL.  
The 24-well plate was incubated in the same manner as NHEK-adult with media 
supernatants being removed and frozen at -80°C for ELISA analysis of cytokine and 
chemokine expression.   
HUMAN SKIN CELLS CHALLENGED WITH IL-1α, IL-1β, AND SS EXTRACT 
 Preliminary studies were performed to determine the optimum dosage of IL-1α 
and IL-1β in which to stimulate the cells.  Briefly, NHEK-Ad were seeded into 4 48-well 
tissue culture treated plates at 10,000 cells/well and allowed to grow to confluence using 
KGM-2.  After reaching confluence, media was aspirated off each well and replaced with 
either IL-1α at 1ng/mL, IL-1β at 1ng/mL, SS extract at 100, 50, 25, and 12.5μg/mL, or 
combinations of SS extract with either IL-1α or IL-1β.   For both IL-1α and IL-1β, the 
plates were incubated for two distinct times of 8 and 24 hours at 37°C and 5-7% CO2.  
After the appropriate incubation times, media supernatants were removed and stored at -
80°C until further cytokine and chemokine analysis via ELISA.   
 In addition, NHDF were challenged with IL-1α, IL-1β, and/or SS extract for 8 
and 24 hours with cell culture supernatant being removed and stored at -80°C for further 
cytokine and chemokine analysis via ELISA.   
KERATINOCYTES STIMULATED WITH SS AND TNF-α FOR 48 HOURS 
 Preliminary studies showed that TNF-α at 10ng/mL induces up-regulation of 
CTACK above constitutive levels at 48 hours of exposure from NHEK-Adult.   
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 Briefly, NHEK-Adult were plated into individual wells of one 48-well tissue 
culture treated plate and allowed to grow to confluency using KGM-2.  Upon reaching 
confluency, individual wells (n=3) were stimulated with either TNF-α, SS extract, or SS 
extract and TNF-α.  Cell-free supernatants were collected at the end of 48 hours of 
incubation and stored at -80°C until an ELISA for CTACK could be done.       
KERATINOCYTES STIMULATED WITH CYSTATIN A, TNF-α AND SS EXTRACT 
 NHEK-Adult were plated into individual wells of one 48-well tissue culture 
treated plate and allowed to grow to confluency using KGM-2.  Cells were then 
stimulated with either TNF-α, Cystatin A, or SS extract for 8 hours.  Cell-free 
supernatants were removed and stored at -80°C until ELISA analysis could be done.          
 CYTOKINE AND CHEMOKINE DETECTION 
 Cell culture supernatants removed from human skin cells in vitro were assayed for 
the presence of cytokines and chemokines using enzyme-linked immunosorbent assays 
(ELISA).  DuoSet® ELISA Development System kits for IL-6, IL-8 (CXCL8), IL-1ra, 
IL-1α, IL-1β, VEGF, G-CSF, GM-CSF, TGF-α, GRO-α, TSLP, TARC (CCL17), and 
CTACK (CCL27) were obtained from R&D Systems, Inc. (Minneapolis, Minn., USA).  
All assays were performed according to the manufacturer’s instructions. 
RECOMBINANT HUMAN CYTOKINES 
 Recombinant human TNF-α, IL-4, IL-13, and IL-17 were obtained from R&D 
Systems, Inc. (Minneapolis, Minn., USA) while recombinant human IL-1α and IL-1β 
were obtained from eBioscience.  Each vial of lyophilized TNF-α, IL-4, IL-13, and IL-17 
was reconstituted using 0.1% BSA in phosphate-buffered saline while IL-1α and IL-1β 
were diluted in 1.0% BSA in phosphate-buffered saline.  Individual cytokines were 
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aliquoted into microcentrifuge tubes and frozen at -80°C.  Upon use, each volume of 
cytokine in the microcentrifuge tube was removed from -80°C, allowed to thaw at room 
temperature, and diluted in appropriate growth medium.  
CYSTATIN A 
Recombinant Human Cystatin A was purchased from R&D Systems, Inc. 
(Minneapolis, Minn., USA).  The vial of lyophilized Cystatin A was reconstituted with 
diluent comprised of 25mM Tris, 0.1M NaCl, pH 7.5 to give a stock solution of 
0.1mg/mL.  The stock solution was aliquoted into individual microcentrifuge tubes and 
frozen at -80°C.   
STATISTICAL ANALYSIS 
Data are reported as mean ± SD of the cytokine levels in the cell-free culture 
supernatant.  Sample size (n) in each group is n=3 unless otherwise noted.  A Student’s 
two-tailed t-test was used to compare means between different groups.  Differences 
between groups where p≤ 0.05 are considered significant.    
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RESULTS 
Human skin cells challenged with Sarcoptes scabiei var. canis whole-body extract 
NHEK-neonatal 
IL-6 
 Cultured keratinocytes constitutively expressed small amounts of IL-6 (Table 1, 
Fig. 1).  Keratinocytes stimulated with LPS did not increase expression levels of IL-6.  In 
measuring a dose response of keratinocytes to SS extract, IL-6 was only significantly 
increased (p< 0.05) above constitutive expression at the highest scabies extract 
concentration tested (100μg/mL).  Addition of LPS with increasing doses of SS extract 
resulted in increased IL-6 expression (p< 0.05) above LPS-induced levels for the two 
highest scabies extract concentrations tested (50 and 100μg/mL).   
IL-8 (CXCL8) 
 Cultured keratinocytes did not constitutively express IL-8 (Table 1).  Neither LPS 
nor SS extract at any dosage induced increased expression of IL-8 from keratinocytes.   
IL-1ra 
 Keratinocytes constitutively expressed large amounts of IL-1ra (Table 1, Fig. 2).  
Keratinocytes stimulated with LPS did not result in increased expression levels of IL-1ra.  
The dose response of NHEK-neonatal to SS extract resulted in significant down-
regulation (p< 0.05) of IL-1ra compared to constitutive expression at scabies extract 
dosages of 25, 50, and 100μg/mL.  By comparison, addition of LPS to increasing doses 
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of SS extract resulted in down-regulation of IL-1ra at the scabies extract concentrations 
of 12.5, 25, and 50μg/mL.   
GRO-α (CXCL1) 
 Keratinocytes constitutively expressed GRO-α (Table 1, Fig. 3).  Stimulation with 
LPS did not induce increased expression of GRO-α from keratinocytes.  Keratinocytes 
stimulated with SS extract increased expression of GRO-α (p< 0.05) in a dose-dependent 
manner with the three highest scabies extract concentrations tested (25, 50, and 
100μg/mL).  In addition, LPS and SS extract together induced GRO-α in a dose 
dependent manner relative to increasing SS extract concentrations.   
TGF-α 
 Keratinocytes constitutively expressed small amounts of TGF-α (Table 1, Fig. 4).  
Stimulation with LPS did not induce increased expression of TGF-α from NHEK-
neonatal.  Keratinocytes stimulated with SS extract resulted in significantly increased 
expression of TGF-α (p< 0.05) above constitutive levels for all SS extract concentrations 
tested.  Keratinocytes stimulated with LPS and SS extract together induced TGF-α (p< 
0.05) only at the highest SS extract concentration tested (100μg/mL).   
TARC (CCL17), CTACK (CCL27), AND TSLP     
 Keratinocytes did not constitutively secrete TARC, CTACK, or TSLP (Table 1).  
Stimulation with SS extract, LPS, or SS and LPS did not induce expression of these 
cytokines from NHEK-neonatal.   
 
 
 
30 
 
 
TABLE 1.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS 
extract ± LPS for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                    7.4 ± 4.3        5.2 ± 2       9.6 ± 2.8              15.9 ± 6.3             20.9 ± 5.9 
IL-8      ND          ND            ND           ND                       ND 
IL-1ra             2256 ± 274                1419 ± 467           1519 ± 367           1345 ± 369            1477 ± 228 
GRO-α                290 ± 6.8                  417 ± 112               553 ± 34              842 ± 116              982 ± 139 
TGF-α                  9 ± 3.4                      18 ± 3.8                 18 ± 4.4                33 ± 12                  38 ± 12 
TARC                     ND                            ND                         ND                        ND                       ND 
CTACK                  ND                            ND                         ND                        ND                       ND 
TSLP                      ND                            ND                         ND                        ND                       ND 
 
 
Cytokine   LPS                          SS (μg/mL) + LPS (50ng) 
  (50ng)          12.5            25            50                        100 
 
IL-6                    5.4 ± 3.6                    3.7 ± 4.5                8.0 ± 1.5             14.7 ± 2.1             22.4 ± 7.4  
IL-8      ND          ND            ND           ND                       ND 
IL-1ra             2107 ± 242                1065 ± 332            1262 ± 201          1469 ± 217           1237 ± 543 
GRO-α                279 ± 29                     446 ± 28               584 ± 35              859 ± 116           1160 ± 104 
TGF-α                  11 ± 4.3                      16 ± 5                    17 ± 5                   27 ± 9                  39 ± 9          
TARC                     ND                            ND                         ND                        ND                       ND 
CTACK                  ND                            ND                         ND                        ND                       ND 
TSLP                      ND                            ND                         ND                        ND                       ND 
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Figure 1.  Effect of S. scabiei extract on IL-6 (pg/mL) expression from normal human epidermal 
keratinocytes.  Cells were incubated with varying doses of SS extract for 24 hours.  Data are 
means ± SD (n=3).  *p< 0.05 for SS compared to control, #p< 0.05 for SS + LPS compared to 
LPS.     
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Figure 2.  Effect of S. scabiei extract on IL-1ra (pg/mL) expression from normal human 
epidermal keratinocytes.  Cells were incubated with varying doses of SS extract for 24 hours.  
Data are means ± SD (n=3).  *p< 0.05 for SS compared to control, #p< 0.05 for SS + LPS 
compared to LPS.   
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Figure 3.  Effect of S. scabiei extract on GRO-α (pg/mL) expression from normal human 
epidermal keratinocytes.  Cells were incubated with varying doses of SS extract for 24 hours.  
Data are means ± SD (n=3).  *p< 0.005 for SS compared to control, **p< 0.001 for SS compared 
to control, #p< 0.005 for SS + LPS compared to LPS, ##p< 0.001 for SS + LPS compared to LPS.   
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Figure 4.  Effect of S. scabiei extract on TGF-α (pg/mL) expression from normal human 
epidermal keratinocytes.  Cells were incubated with varying doses of SS extract for 24 hours.  
Data are means ± SD (n=3).  *p< 0.05 for SS compared to control, #p< 0.05 for SS + LPS 
compared to LPS. 
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NHDF 
IL-6 
 Fibroblasts did not constitutively secrete IL-6 at 12 or 24 hours (Tables 2 and 3, 
Figs. 5 and 6).  Fibroblasts stimulated with LPS significantly (p< 0.05) up-regulated 
expression of IL-6 at both 12 and 24 hours of exposure.  Likewise, fibroblasts stimulated 
with SS extract (50 and 100μg/mL) or SS extract and LPS induced significant increases 
(p< 0.05) in IL-6 at 12 and 24 hours compared to constitutive or LPS-induced expression.    
IL-8 
 Fibroblasts constitutively expressed IL-8 at both 12 and 24 hours (Tables 2 and 3, 
Figs. 7 and 8).  Stimulation with LPS significantly (p< 0.05) increased IL-8 expression 
from fibroblasts at both 12 and 24 hours.  At 12 hours, SS extract at 50 and 100μg/mL 
down-regulated IL-8 expression from fibroblasts below constitutive by 78% and 82%, 
respectively.  In addition, SS (50 and 100μg/mL) and LPS reduced IL-8 from fibroblasts 
by 76% and 87% below LPS-induced expression, respectively.  By comparison, at 24 
hours SS extract at 50 and 100μg/mL down-regulated IL-8 expression from fibroblasts 
below constitutive by 53% and 77%, respectively.  Also at 24 hours, fibroblasts 
stimulated with SS (50 and 100μg/mL) and LPS reduced IL-8 expression by 42% and 
82%, respectively, compared to LPS-induced cells.   
G-CSF and GM-CSF 
 Fibroblasts did not constitutively express G-CSF or GM-CSF at 12 or 24 hours 
(Tables 2 and 3).  Stimulation with SS, LPS, or SS and LPS did not induce expression of 
either G-CSF or GM-CSF from fibroblasts at 12 and 24 hours.   
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TARC (CCL17), CTACK (CCL27), and TSLP   
 Fibroblasts did not constitutively express TARC, CTACK, or TSLP at 12 or 24 
hours (Tables 2 and 3).  Stimulation with SS, LPS, or SS and LPS did not induce 
expression of TARC, CTACK, or TSLP from fibroblasts at 12 and 24 hours.   
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TABLE 2.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
LPS for 12 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  
 
 
Cytokine  Media                   SS (μg/mL)                    LPS               SS (μg/mL) + LPS (50ng) 
  Control            50                   100             (50ng)                  50                   100 
 
IL-6                       ND            123 ± 45           188 ± 6       134 ± 12            307 ± 19           215 ± 7             
IL-8               251 ± 12         55 ± 9               44 ± 3        346 ± 24             83 ± 12             44 ± 2  
G-CSF                    ND               ND                     ND               ND                   ND     ND         
GM-CSF                 ND               ND                     ND              ND                   ND     ND         
TARC                     ND               ND                     ND               ND                   ND                  ND 
CTACK                  ND               ND                     ND               ND                   ND                  ND 
TSLP                      ND               ND                     ND               ND                   ND                  ND 
 
 
 
TABLE 3.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
LPS for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  
 
 
Cytokine  Media                   SS (μg/mL)                    LPS               SS (μg/mL) + LPS (50ng) 
  Control            50                    100            (50ng)                  50                   100 
 
IL-6                       ND             199 ± 33         283 ± 28       176 ± 36            318 ± 56         391 ± 117                
IL-8               292 ± 14        136 ± 22          66 ± 10        383 ± 17            220 ± 37            68 ± 5 
G-CSF                    ND               ND                     ND               ND                   ND     ND         
GM-CSF                 ND               ND                     ND              ND                   ND     ND         
TARC                     ND               ND                     ND               ND                   ND                  ND 
CTACK                  ND               ND                     ND               ND                   ND                  ND 
TSLP                      ND               ND                     ND               ND                   ND                  ND 
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Figures 5 and 6.  Effect of S. scabiei extract on IL-6 expression from normal human dermal 
fibroblasts.  Cells were incubated with SS extract (50 and 100μg/mL), LPS, or SS and LPS for 12 
and 24 hours.  Data are means ± SD (n=3).  Fig 5 = *p< 0.005 for LPS compared to control, **p< 
0.05 for SS compared to control, ***p< 0.005 for SS compared to control, #p< 0.005 for SS and 
LPS compared to LPS.  Fig 6 = *p< 0.005 for LPS compared to control, **p< 0.005 for SS 
compared to control, #p< 0.05 for SS and LPS compared to LPS.      
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Figures 7 and 8.  Effect of S. scabiei extract on IL-8 expression from normal human dermal 
fibroblasts.  Cells were incubated with SS extract (50 and 100μg/mL), LPS, or SS and LPS for 12 
and 24 hours.  Data are means ± SD (n=3).  Fig 7 = *p< 0.05 for LPS compared to control, **p< 
0.005 for SS compared to control, #p< 0.005 for SS and LPS compared to LPS.  Fig 8 = *p< 0.05 
for LPS compared to control, **p< 0.05 for SS compared to control, #p< 0.05 for SS and LPS 
compared to LPS, ##p< 0.005 for SS and LPS compared to LPS. 
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Epidermal keratinocytes challenged with S. scabiei var. canis extract + TNF-α.  
Preliminary study 
 A dose response study to determine the optimum dosage of TNF-α in which to 
stimulate the cells showed that TNF-α at 5ng/mL induced the up-regulation of both IL-6 
and IL-8 above constitutive levels at 24 hours (Table 4, Figs. 9 and 10).  In addition, IL-4 
was investigated for a potential synergistic effect with TNF-α, however only TNF-α 
induced the up-regulation of IL-6 and IL-8.  Keratinocytes stimulated with TNF-α, IL-4, 
or TNF-α and IL-4 showed no expression of TARC, CTACK, TSLP, or VEGF at 24 
hours.   
IL-6 
 Keratinocytes in vitro constitutively expressed low amounts of IL-6 at 8 and 24 
hours (Tables 5 and 6, Fig. 11).  This expression was significantly (p< 0.05) increased at 
both 8 and 24 hours when keratinocytes were stimulated with TNF-α at 5ng/mL.  At 8 
and 24 hours, keratinocytes stimulated with TNF-α and varying doses of SS extract (12.5, 
25, 50, and 100μg/mL) up-regulated expression of IL-6 in a dose-dependent manner 
above TNF-α-induced expression. 
IL-8 
 Cultured keratinocytes constitutively expressed IL-8 at both 8 and 24 hours 
(Tables 5 and 6, Fig. 12).  Upon TNF-α stimulation, keratinocytes significantly (p< 0.05) 
up-regulated IL-8 expression above constitutive at both 8 and 24 hours by 13- and 11-
fold, respectively.  Keratinocytes stimulated with TNF-α and increasing concentrations of 
SS extract undergo a significant (p< 0.05) dose-dependent down-regulation of IL-8 at 
both 8 and 24 hours. 
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IL-1ra 
 Keratinocytes constitutively expressed large amounts of IL-1ra at both 8 and 24 
hours in culture (Tables 5 and 6, Fig. 13).  Stimulation with TNF-α for 24 hours induced 
a significant (p< 0.05) increase in IL-1ra above constitutive expression.  Down-regulation 
of TNF-α-induced IL-1ra expression is seen with keratinocytes stimulated with TNF-α 
and SS extract at concentrations of 25 and 100μg/mL for 24 hours.   
GRO-α 
 Constitutive expression of GRO-α from keratinocytes occured at both 8 and 24 
hours in vitro (Tables 5 and 6, Fig. 14).  Stimulation of keratinocytes with TNF-α 
significantly (p< 0.05) up-regulated GRO-α expression above constitutive levels at 8 and 
24 hours by 5.4- and 4.0-fold increases, respectively.  Keratinocytes stimulated with 
TNF-α and SS extract (100μg/mL) for 8 hours show increased expression of GRO-α 
above TNF-α-induced levels.  Keratinocytes stimulated for 24 hours with TNF-α and 
varying doses of SS extract reached maximum expression levels resulting in the cells 
inability to show any distinction with such high amounts of GRO-α expression.   
TGF-α 
 Keratinocytes constitutively produced small amounts of TGF-α at both 8 and 24 
hours in culture (Tables 5 and 6, Fig. 15).  Incubation of keratinocytes with TNF-α 
induced an up-regulation (p< 0.05) of TGF-α compared to that constitutively expressed at 
24 hours, but not at 8 hours.  Stimulation with SS and TNF-α increased TGF-α 
expression at both 8 and 24 hours in a dose-dependent manner above TNF-α-induced 
expression.   
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TABLE 4.  Cytokine production (pg/mL) from NHEK-neonatal challenged with 
TNF-α ± IL-4 for 24 hours. Data are expressed as means ± SD (n=3).  ND = not 
detected. 
 
 
      Cytokines (pg/mL) 
   IL-6          IL-8                 TARC       CTACK   TSLP        VEGF 
Media Control                    ND              3.9 ± 3.3                ND             ND                ND            ND 
 
TNF-α (ng/mL)                
0.5             9.5 ± 1.5        39.4 ± 9.5               ND             ND                ND            ND 
5.0            19.3 ± 2.5         98 ± 7.0                ND             ND                ND            ND 
50             33 ± 3.6      157 ± 25                ND             ND                ND            ND 
 
IL-4 (ng/mL) 
1.0                ND               8.8 ± 1.2               ND             ND                ND            ND 
10                 ND               6.2 ± 1.0               ND             ND                ND            ND 
 
TNF-α (ng/mL)  
+ IL-4 (ng/mL) 
0.5 + 10             8.7 ± 0.7         47 ± 9.7                 ND             ND                ND            ND 
0.5 + 100             10 ± 1.4         42 ± 2.8                 ND             ND                ND            ND 
5.0 + 1.0              14 ± 1.9         89 ± 15.6               ND             ND                ND            ND 
5.0 + 10              14 ± 0.7         85.4 ± 7.6              ND             ND                ND            ND 
5.0 + 100           12.1 ± 2.5        84 ± 12.4               ND             ND                ND            ND 
50 + 1.0            16.6 ± 1.1        111 ± 22                ND             ND                ND            ND 
50 + 10              18.1 ± 1.1        134 ± 10                ND             ND                ND            ND 
50 + 100           17.2 ± 3.3        114 ± 9.3               ND             ND                ND            ND 
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Figure 9.  Effect of varying doses of TNF-α, IL-4, or TNF-α and IL-4 on IL-6 secretion from 
normal human epidermal keratinocytes.  Cells were incubated for 24 hours.  Data are means ± SD 
(n=3).   
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Figure 10.  Effect of varying doses of TNF-α, IL-4, or TNF-α and IL-4 on IL-8 secretion from 
normal human epidermal keratinocytes.  Cells were incubated for 24 hours.  Data are means ± SD 
(n=3).   
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TABLE 5.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS 
extract + TNF-α for 8 hours. Data are expressed as means ± SD (n=3).    
 
 
 
Cytokine        Media                TNF-α                          SS (μg/mL) + TNF-α (5ng)                               
        Control         (5ng)        12.5                   25               50               100 
 
IL-6        1.6 ± 0.5      35.8 ± 4.2  60.8 ± 14.4       74.4 ± 2.0        86.5 ± 12.8          120.3 ± 11.7         
IL-8       26.4 ± 7.9             344 ± 50           341 ± 57           236 ± 30         93 ± 16.2              47 ± 12.4    
IL-1ra     3130 ± 1037         3642 ± 982       4492 ± 549       3228 ± 286      3511 ± 236           2825 ± 628 
GRO-α       171 ± 40       931 ± 96         1079 ± 109       1203 ± 107      1136 ± 112            1371 ± 144 
TGF-α      27.8 ± 8.0      40.3 ± 0.7         43.4 ± 3.0         48.9 ± 2.6         59.5 ± 5.3            76.5 ± 8.5 
 
 
TABLE 6.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS 
extract + TNF-α for 24 hours. Data are expressed as means ± SD (n=3).    
 
 
 
Cytokine        Media                TNF-α                          SS (μg/mL) + TNF-α (5ng)                               
        Control         (5ng)        12.5                   25               50               100 
 
IL-6        6.3 ± 0.8              78.5 ± 2            109 ± 21          124 ± 10.2        136 ± 18                161 ± 11    
IL-8       70.8 ± 1.0            813 ± 170         838 ± 117          595 ± 81          333 ± 30                140 ± 11 
IL-1ra       3522 ± 50          4372 ± 459       3228 ± 1114       3206 ± 57       3392 ± 978            2041 ± 218 
GRO-α       524 ± 29            2072 ± 273        2309 ± 77          2290 ± 72        2283 ± 27             2248 ± 140 
TGF-α       39.6 ± 6.1              88 ± 9               89 ± 4                92 ± 2            129 ± 6                  150 ± 6 
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Figure 11.  Effect of S. scabiei extract on the TNF-α-induced expression of IL-6 by normal 
human epidermal keratinocytes.  Cells were incubated with TNF-α (5ng/mL) and varying doses 
of S. scabiei extract (12.5, 25, 50, and 100μg/mL) for 8 and 24 hours.  Data are means ± SD 
(n=3).  *p< 0.0002 for TNF-α compared to control, **p< 0.05 for TNF-α and SS compared to 
TNF-α, ***p< 0.005 for TNF-α and SS compared to TNF-α, #p< 0.001 for TNF-α compared to 
control, ##p< 0.002 for TNF-α and SS compared to TNF-α, ###p< 0.01 for TNF-α and SS 
compared to TNF-α.   
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Figure 12.  Effect of S. scabiei extract on the TNF-α-induced expression of IL-8 by normal 
human epidermal keratinocytes.  Cells were incubated with TNF-α (5ng/mL) and varying doses 
of S. scabiei extract (12.5, 25, 50, and 100μg/mL) for 8 and 24 hours.  Data are means ± SD 
(n=3).  *p< 0.001 for TNF-α compared to control, **p< 0.05 for TNF-α and SS compared to 
TNF-α, ***p< 0.005 for TNF-α and SS compared to TNF-α, #p< 0.005 for TNF-α compared to 
control, ##p< 0.01 for TNF-α and SS compared to TNF-α, ###p< 0.005 for TNF-α and SS 
compared to TNF-α.   
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Figure 13.  Effect of S. scabiei extract on the TNF-α-induced expression of IL-1ra by normal 
human epidermal keratinocytes.  Cells were incubated with TNF-α (5ng/mL) and varying doses 
of S. scabiei extract (12.5, 25, 50, and 100μg/mL) for 8 and 24 hours.  Data are means ± SD 
(n=3).  #p< 0.05 for TNF-α compared to control, ##p< 0.05 for TNF-α and SS compared to TNF-
α, ###p< 0.005 for TNF-α and SS compared to TNF-α.   
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Figure 14.  Effect of S. scabiei extract on the TNF-α-induced expression of GRO-α by normal 
human epidermal keratinocytes.  Cells were incubated with TNF-α (5ng/mL) and varying doses 
of S. scabiei extract (12.5, 25, 50, and 100μg/mL) for 8 and 24 hours.  Data are means ± SD 
(n=3).  *p< 0.005 for TNF-α compared to control, **p< 0.05 for TNF-α and SS compared to 
TNF-α, #p< 0.005 for TNF-α compared to control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
500
1000
1500
2000
2500
3000
Media TNF‐a  TNF‐a + 12.5 TNF‐a + 25 TNF‐a + 50 TNF‐a + 100
G
RO
‐α
 p
g/
m
L
SS (μg/mL)
NHEK‐neonatal challenged with TNF‐α & SS whole‐body extract
8 hour
24 hour*
#
**
50 
 
 
 
Figure 15.  Effect of S. scabiei extract on the TNF-α-induced expression of TGF-α by normal 
human epidermal keratinocytes.  Cells were incubated with TNF-α (5ng/mL) and varying doses 
of S. scabiei extract (12.5, 25, 50, and 100μg/mL) for 8 and 24 hours.  Data are means ± SD 
(n=3).  *p< 0.05 for TNF-α and SS  compared to TNF-α, **p< 0.005 for TNF-α and SS compared 
to TNF-α, #p< 0.005 for TNF-α compared to control, ##p< 0.05 for TNF-α and SS compared to 
TNF-α. 
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Epidermal keratinocytes challenged with TNF-α and either S. scabiei var. canis 
supernatant or S. scabiei var. canis pellet 
IL-6 
 Cultured keratinocytes constitutively expressed IL-6 at low levels for both 8 and 
24 hours (Tables 7-10, Figs. 16 and 17).  Keratinocytes stimulated with TNF-α 
significantly increased (p< 0.05) expression of IL-6 above constitutive at both 8 and 24 
hours of exposure.  Stimulation of keratinocytes with either SS supernatant or SS re-
suspended pellet and TNF-α induced a dose-dependent up-regulation in IL-6 expression 
for 8 hours of exposure compared to TNF-α-induced expression.  At 24 hours, 
keratinocytes stimulated with SS supernatant expressed an increase in IL-6 only at the 
highest dose of SS supernatant tested.  No significant change occurred above TNF-α-
induced levels for keratinocytes stimulated with SS re-suspended pellet and TNF-α for 24 
hours.   
IL-8 
 Keratinocytes did not constitutively express IL-8 at either 8 or 24 hours (Tables 7-
10, Figs. 18 and 19).  Stimulation with TNF-α increased (p< 0.05) IL-8 expression from 
keratinocytes at 8 and 24 hours.  Co-incubation with TNF-α and SS supernatant induced 
significantly increased IL-8 expression (p< 0.05) in a dose-dependent manner relative to 
TNF-α-induced keratinocytes at 8 hours.  Keratinocytes stimulated with SS re-suspended 
pellet and TNF-α slightly increased expression of IL-8 above TNF-α-induced levels at 8 
hours, however IL-8 expression returned to TNF-α-induced levels at the highest 
concentration of SS re-suspended pellet tested.  Keratinocytes stimulated with TNF-α and 
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either SS supernatant or SS re-suspended pellet induced increased IL-8 expression above 
TNF-α-induced levels at 24 hours.   
GRO-α 
 Keratinocytes constitutively produced GRO-α in vitro (Tables 7-10, Figs. 20 and 
21).  Stimulation with TNF-α induced up-regulation (p< 0.05) of GRO-α from epidermal 
keratinocytes at 8 and 24 hours of exposure.  There was no increased expression of GRO-
α from keratinocytes stimulated with TNF-α and SS supernatant at either 8 or 24 hours, 
however there was an increase (p< 0.05) in GRO-α expression when keratinocytes were 
stimulated with TNF-α and SS re-suspended pellet for 8 hours.   
TGF-α 
 Cultured keratinocytes constitutively produced only small amounts of TGF-α 
(Tables 7-10, Figs. 22 and 23).  Stimulation with TNF-α induced only a slight up-
regulation (p< 0.05) of TGF-α from keratinocytes at 24 hours but not 8 hours.  Addition 
of SS supernatant or SS re-suspended pellet with TNF-α dose-dependently increased 
TGF-α expression from keratinocytes at both 8 and 24 hours after challenge.   
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TABLE 7.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS  
extract supernatant + TNF-α for 8 hours. Data are expressed as means ± SD (n=3).  
ND = not detected    
 
 
 
Cytokine        Media                TNF-α                      SS supernatant (concentration) + TNF-α (5ng)                              
        Control                 (5ng)   Lowest                                                                   Highest 
 
IL-6      19.8 ± 2.0             73 ± 10             76 ± 11             105 ± 12             134 ± 15            166 ± 17    
IL-8           ND                 208 ± 36            195 ± 39           347 ± 22             406 ± 17             557 ± 54 
GRO-α        91 ± 8               448 ± 52             388 ± 43           493 ± 17             486 ± 15             590 ± 79 
TGF-α      17.7 ± 3.3          23.7 ± 3.3            26 ± 3.8            37 ± 4.4              42 ± 2.6              48 ± 1.5 
 
 
TABLE 8.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS 
extract pellet + TNF-α for 8 hours. Data are expressed as means ± SD (n=3).  ND = not 
detected    
 
 
 
Cytokine        Media                TNF-α                          SS Pellet (concentration) + TNF-α (5ng)           
        Control                 (5ng)     Lowest                                                                  Highest 
 
IL-6       22 ± 0.2               83 ± 3.8              84 ± 8.8          95 ± 6.0              122 ± 5.0           156 ± 16 
IL-8           ND                  250 ± 17             299 ± 22         297 ± 18              378 ± 17            274 ± 27   
GRO-α       99 ± 6.5              505 ± 61              552 ± 61         574 ± 43               642 ± 5            708 ± 54 
TGF-α       17 ± 2.5               24 ± 4.2              29 ± 4.0          29 ± 3.0               37 ± 1.1            40.6 ± 1.8 
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TABLE 9.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS  
extract supernatant + TNF-α for 24 hours. Data are expressed as means ± SD (n=3).  
ND = not detected    
 
 
 
Cytokine        Media                TNF-α                      SS supernatant (concentration) + TNF-α (5ng)         
        Control                 (5ng)     Lowest                                                                  Highest 
 
IL-6      31.5 ± 1.8             166 ± 15            171 ± 7.7           187 ± 17             179 ± 13           209 ± 10 
IL-8         ND                    400 ± 10            608 ± 76             747 ± 61             633 ± 52          797 ± 35     
GRO-α       268 ± 17            1265 ± 176        1156 ± 179         1161 ± 93            879 ± 97           892 ± 62   
TGF-α       41 ± 1.5               63 ± 6.6             107 ± 6.2          137 ± 7.9             154 ± 1.5          204 ± 13 
 
 
TABLE 10.  Cytokine production (pg/mL) from NHEK-neonatal challenged with SS 
extract pellet + TNF-α for 24 hours. Data are expressed as means ± SD (n=3).  ND = 
not detected    
 
 
 
Cytokine        Media                TNF-α                          SS Pellet (concentration) + TNF-α (5ng)        
        Control                 (5ng)     Lowest                                                                  Highest 
 
IL-6       27.3 ± 4.2            155 ± 20             177 ± 7.1           169 ± 23             154 ± 4.1         208 ± 63      
IL-8           ND                  401 ± 74             683 ± 35             669 ± 59             599 ± 52         574 ± 192 
GRO-α        248 ± 17           1278 ± 267         1459 ± 114         1292 ± 146         1062 ± 94        1166 ± 259 
TGF-α       36.3 ± 6.9           66.2 ± 2.1           96.7 ± 4.5           93.9 ± 5.9           125 ± 5.9         141 ± 30 
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Figures 16 and 17.  Effect of S. scabiei extract supernatant or S. scabiei extract pellet on the TNF-α-
induced expression of IL-6 at 8 and 24 hours from normal human epidermal keratinocytes.  Data are means 
± SD (n=3).  Fig. 16.  *p< 0.005 for TNF-α compared to control, **p< 0.05 for SS and TNF-α compared to 
TNF-α, ***p< 0.005 for SS and TNF-α compared to TNF-α, #p< 0.005 for TNF-α compared to control, 
##p< 0.05 for SS and TNF-α compared to TNF-α.  Fig. 17.  *p< 0.005 for TNF-α compared to control, 
**p< 0.05 for SS and TNF-α compared to TNF-α, #p< 0.0005 for TNF-α compared to control.               
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Figures 18 and 19.  Effect of S. scabiei extract supernatant or S. scabiei extract pellet on the TNF-α-
induced expression of IL-8 at 8 and 24 hours from normal human epidermal keratinocytes.  Data are means 
± SD (n=3).  Fig. 18.  *p< 0.05 for TNF-α compared to control, **p< 0.05 for SS and TNF-α compared to 
TNF-α, ***p< 0.005 for SS and TNF-α compared to TNF-α, #p< 0.005 for TNF-α compared to control, 
##p< 0.05 for SS and TNF-α compared to TNF-α.  Fig. 19.  *p< 0.005 for TNF-α compared to control, 
**p< 0.05 for SS and TNF-α compared to TNF-α, #p< 0.005 for TNF-α compared to control, ##p< 0.05 for 
SS and TNF-α compared to TNF-α.                 
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Figures 20 and 21.  Effect of S. scabiei extract supernatant or S. scabiei extract pellet on the TNF-α-
induced expression of GRO-α at 8 and 24 hours from normal human epidermal keratinocytes.  Data are 
means ± SD (n=3).  Fig. 20.  *p< 0.005 for TNF-α compared to control, #p< 0.005 for TNF-α compared to 
control, ##p< 0.05 for SS and TNF-α compared to TNF-α.  Fig. 21.  *p< 0.005 for TNF-α compared to 
control, **p< 0.05 for SS and TNF-α compared to TNF-α, #p< 0.005 for TNF-α compared to control.   
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Figures 22 and 23.  Effect of S. scabiei extract supernatant or S. scabiei extract pellet on the TNF-α-
induced expression of TGF-α at 8 and 24 hours from normal human epidermal keratinocytes.  Data are 
means ± SD (n=3).  Fig. 22.  *p< 0.05 for TNF-α compared to control, **p< 0.005 for SS and TNF-α 
compared to TNF-α, #p< 0.005 for SS and TNF-α compared to TNF-α.  Fig. 23.  *p< 0.05 for TNF-α 
compared to control, **p< 0.005 for SS and TNF-α compared to TNF-α, #p< 0.05 for TNF-α compared to 
control, ##p< 0.005 for SS and TNF-α compared to TNF-α.   
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Human skin cells challenged with S. scabiei var. canis extract ± TNF-α and IL-17 
Preliminary Study 
 A dose response study to determine the optimum dosage of TNF-α and IL-17 in 
which to synergistically stimulate human skin cells showed that TNF-α at 5ng/mL and 
IL-17 at 10ng/mL induced increased expression of IL-6 and IL-8 above constitutive 
levels, TNF-α-induced levels, and IL-17-induced levels (Tables 11 and 12, Figs. 24-27).  
In addition, fibroblasts synergistically stimulated with TNF-α and IL-17 at the above 
concentrations induced increased G-CSF and GM-CSF levels above constitutive levels, 
TNF-α-induced levels, and IL-17-induced levels (Table 12, Figs. 28 and 29).  
Keratinocytes synergistically stimulated with TNF-α and IL-17 did not express TARC, 
CTACK, TSLP, IL-1ra, GRO-α, or TGF-α at 24 hours (Table 11).  Fibroblasts 
synergistically stimulated with TNF-α and IL-17 did not express TARC or TSLP at 24 
hours (Table 12).     
NHEK-Adult 
IL-6 
 Keratinocytes did not constitutively express IL-6 at 8 or 24 hours (Tables 13 and 
14), nor did addition of varying doses of SS extract up-regulate this cytokine.  
Stimulation with TNF-α and IL-17 induced a small up-regulation of IL-6 at 8 and 24 
hours, however SS extract with TNF-α and IL-17 did not further increase IL-6.   
IL-8 (CXCL8) 
 Keratinocytes constitutively expressed IL-8 at 8 and 24 hours in culture (Tables 
13 and 14, Figs. 30 and 31).  Stimulation with varying doses of SS extract induced down-
regulation of IL-8 compared to constitutive expression.  Stimulation with TNF-α and IL-
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17 induced keratinocytes to significantly (p< 0.05) up-regulate IL-8 at 8 and 24 hours by 
10- and 5.7-fold, respectively.  Increasing concentrations of SS extract with TNF-α and 
IL-17 dose-dependently down-regulated IL-8 expression from keratinocytes at 8 and 24 
hours (Figs. 30 and 31). 
GRO-α 
 Cultured keratinocytes constitutively expressed GRO-α at 8 and 24 hours (Tables 
13 and 14, Figs. 32 and 33).  Stimulation with varying doses of SS extract increased 
GRO-α expression levels in a dose-dependent manner above constitutive expression.  
Keratinocytes significantly (p< 0.05) up-regulated GRO-α in response to TNF-α and IL-
17 at 8 and 24 hours by 5.5- and 2.8-fold, respectively.  Addition of varying doses of SS 
extract with TNF-α and IL-17 did not increase GRO-α levels above TNF-α/IL-17-
induced levels.   
TGF-α 
 Keratinocytes constitutively secreted small amounts of TGF-α in culture at 8 and 
24 hours (Tables 13 and 14, Figs. 34 and 35).  Stimulation with SS extract at varying 
doses increased TGF-α above constitutive expression from keratinocytes at 8 and 24 
hours.  Keratinocytes stimulated with varying doses of SS extract along with TNF-α and 
IL-17 induced an up-regulation of TGF-α in a dose dependent manner at 8 hours, while 
only SS extract at 100μg/mL with TNF-α and IL-17 significantly (p< 0.05) increased 
TGF-α at 24 hours.   
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NHDF 
IL-6 
 Cultured fibroblasts did not constitutively express IL-6 at 8 or 24 hours (Tables 
15 and 16, Figs. 36 and 37).  Stimulation with varying doses of SS extract induced a 
dose-dependent increase in IL-6 from fibroblasts at 8 hours, while maximum expression 
levels of IL-6 were reached for all doses of SS extract tested at 24 hours.  The synergistic 
effect of TNF-α and IL-17 increased IL-6 expression from fibroblasts, however addition 
of varying doses of SS extract with TNF-α and IL-17 did not increase IL-6 beyond this 
level.   
IL-8 
 Fibroblasts constitutively expressed small amounts of IL-8 for both 8 and 24 
hours (Tables 15 and 16, Figs. 38 and 39).  Stimulation of fibroblasts with increasing 
doses of SS extract at 8 hours resulted initially with an up-regulation of IL-8 at the lowest 
SS extract (12.5μg/mL) tested , however this increased expression shifted toward a dose-
dependent down-regulation of IL-8 with increasing concentrations of SS extract.  At 24 
hours, SS extract increased IL-8 expression above constitutive expression but there was 
no down-regulation effect with increasing SS extract.  Fibroblasts stimulated with TNF-α 
and IL-17 at 8 and 24 hours expressed significant (p< 0.05) increases in IL-8 expression 
at 12- and 7.5-fold each, respectively.  Addition of varying doses of SS extract with TNF-
α and IL-17 did not increase IL-8 expression beyond the levels induced by TNF-α and 
IL-17.   
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G-CSF 
 Cultured fibroblasts did not constitutively express G-CSF at either 8 or 24 hours 
(Tables 15 and 16, Figs. 40 and 41).  Stimulation with varying doses of SS extract did not 
induce G-CSF expression at 8 hours, however SS extract did induce G-CSF up-regulation 
at 24 hours of exposure.  Fibroblasts stimulated with TNF-α and IL-17 significantly (p< 
0.05) up-regulated G-CSF expression at both 8 and 24 hours.  Increasing concentrations 
of SS extract with TNF-α and IL-17 did not modulate G-CSF levels above or below TNF-
α and IL-17-induced levels.   
GM-CSF 
 Fibroblasts did not constitutively express GM-CSF at either 8 or 24 hours (Tables 
15 and 16, Figs. 42 and 43).  Stimulation with varying doses of SS extract did not induce 
GM-CSF expression at 8 hours, however SS extract slightly up-regulated GM-CSF 
expression at 24 hours.  Co-stimulation with TNF-α and IL-17 induced an up-regulation 
of GM-CSF from fibroblasts at 8 and 24 hours.  Stimulation with varying doses of SS 
extract along with TNF-α and IL-17 induced a dose-dependent down-regulation of GM-
CSF from fibroblasts observed at both 8 and 24 hours.                     
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TABLE 11.  Cytokine production (pg/mL) from NHEK-Adult challenged with TNF-
α ± IL-17 for 24 hours. Data are expressed as means ± SD (n=3).  ND = not detected. 
 
 
      Cytokines (pg/mL) 
        IL-6          IL-8          TARC     CTACK      TSLP      IL-1ra      GRO-α      TGF-α   
Media Control            ND     45.3 ± 11.3       ND           ND             ND         ND           ND           ND      
 
TNF-α (ng/mL)                
0.5        ND       157 ± 55          ND           ND             ND         ND           ND           ND      
5.0        ND       406 ± 36          ND           ND             ND         ND           ND           ND      
50   5.8 ± 1.4    413 ± 72          ND           ND             ND         ND           ND           ND      
 
IL-17 (ng/mL) 
0.1                             ND        63 ± 18           ND           ND             ND         ND           ND           ND      
1.0       ND        67 ± 12           ND           ND             ND         ND           ND           ND      
10                      ND      110 ± 16.4        ND           ND             ND         ND           ND           ND      
100                     ND      160 ± 16           ND           ND             ND         ND           ND           ND      
 
TNF-α (ng/mL)  
+ IL-17 (ng/mL) 
5.0 + 0.1       ND       356 ± 101          ND           ND             ND         ND           ND           ND         
5.0 + 1.0              6.2 ± 0.4    509 ± 8.6           ND           ND             ND         ND           ND           ND      
5.0 + 10             15.2 ± 3.1    692 ± 30            ND           ND             ND         ND           ND           ND      
5.0 + 100           27.3 ± 2.1    756 ± 21            ND           ND             ND         ND           ND           ND      
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Figure 24.  Effect of TNF-α and IL-17 on IL-6 expression from normal human epidermal 
keratinocytes challenged for 24 hours.  Data are expressed as means ± SD (n=3).   
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Figure 25.  Effect of TNF-α and IL-17 on IL-8 expression from normal human epidermal 
keratinocytes challenged for 24 hours.  Data are expressed as means ± SD (n=3).   
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TABLE 12.  Cytokine production (pg/mL) from NHDF challenged with TNF-α ± IL-
17 for 24 hours. Data are expressed as means ± SD (n=3).  ND = not detected. 
 
 
      Cytokines (pg/mL) 
          IL-6                 IL-8              G-CSF            GM-CSF             TARC           TSLP              
Media Control        24.2 ± 3.8        80.1 ± 47.8          ND                7.0 ± 0                   ND               ND 
 
TNF-α (ng/mL)                
0.5                  299 ± 6.1        4969 ± 251            ND             40.7 ± 2.4                ND               ND 
5.0     579 ± 25         5510 ± 22         9.3 ± 6.1          59.3 ± 5                  ND               ND 
50     649 ± 18         5871 ± 41         5.5 ± 1.8        67.6 ± 11.2               ND               ND 
 
IL-17 (ng/mL) 
0.1                          27.9 ± 2.6             ND                  ND                   ND                      ND              ND 
1.0    35.7 ± 3.6          79 ± 24               ND                   ND                      ND              ND 
10                   102 ± 12          163 ± 38           7.7 ± 4.2              ND                      ND              ND 
100                  116 ± 4.1         206 ± 34           4.6 ± 3.8              ND                      ND              ND 
 
TNF-α (ng/mL)  
+ IL-17 (ng/mL) 
5.0 + 0.1   1324 ± 122       5561 ± 178       8.0 ± 2.4         48.8 ± 6.1                 ND               ND 
5.0 + 1.0               3451 ± 627       6473 ± 293       138 ± 21         93.7 ± 6.3                 ND                ND 
5.0 + 10                6035 ± 984       6958 ± 102       496 ± 35        189.3 ± 8.7                ND               ND 
5.0 + 100              5979 ± 245       7121 ± 100       715 ± 24         271 ± 10.3                ND               ND 
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Figures 26 and 27.  Effect of TNF-α and IL-17 on IL-6 and IL-8 expression from normal human 
dermal fibroblasts stimulated for 24 hours.  Data are expressed as means ± SD (n=3).   
 
 
 
 
 
 
 
 
 
 
 
 
0 1000 2000 3000 4000 5000 6000 7000 8000
Media
TNF‐a 0.5ng/mL
TNF‐a 5.0ng/mL
TNF‐a 50ng/mL
IL‐17 0.1ng/mL
IL‐17 1.0ng/mL
IL‐17 10ng/mL
IL‐17 100ng/mL
TNF‐a 5.0ng/mL + IL‐17 0.1ng/mL
TNF‐a 5.0ng/mL + IL‐17 1.0ng/mL
TNF‐a 5.0ng/mL + IL‐17 10ng/mL
TNF‐a 5.0ng/mL + IL‐17 100ng/mL
IL‐6 pg/mL
NHDF challenged with TNF‐α ± IL‐17 for 24 hours
0 1000 2000 3000 4000 5000 6000 7000 8000
Media
TNF‐a 0.5ng/mL
TNF‐a 5.0ng/mL
TNF‐a 50ng/mL
IL‐17 0.1ng/mL
IL‐17 1.0ng/mL
IL‐17 10ng/mL
IL‐17 100ng/mL
TNF‐a 5.0ng/mL + IL‐17 0.1ng/mL
TNF‐a 5.0ng/mL + IL‐17 1.0ng/mL
TNF‐a 5.0ng/mL + IL‐17 10ng/mL
TNF‐a 5.0ng/mL + IL‐17 100ng/mL
IL‐8 pg/mL
NHDF challenged with TNF‐α ± IL‐17 for 24 hours
68 
 
 
 
 
Figures 28 and 29.  Effect of TNF-α and IL-17 on G-CSF and GM-CSF expression from normal 
human dermal fibroblasts stimulated for 24 hours.  Data are expressed as means ± SD (n=3).   
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TABLE 13.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  TNF-α/IL-17 for 8 hours.  Data are expressed as means ± SD (n=3).  ND = 
not detected.  Stim = TNF-α (5ng/mL) + IL-17 (10ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                             ND                         ND                       ND                    3.8 ± 1.5      
IL-8              36.8 ± 5.7                        ND                         ND                  4.2 ± 2.3                9.0 ± 2.9 
GRO-α             90.9 ± 10.8                  120 ± 4.5               145 ± 12.1            171 ± 8.7               227 ± 12 
TGF-α               18.4 ± 3.6                  39.9 ± 2.3               42.3 ± 4.2             49.9 ± 5.9              85.4 ± 4.3 
 
 
Cytokine           TNF-α (5ng/mL)                          SS (μg/mL) + Stim  
                          IL-17 (10ng/mL)                 12.5                         25                   50                       100 
  
IL-6                   5.3 ± 2.2                             4.4 ± 0.7                8.7 ± 0.9              8.9 ± 1.0            20.1 ± 4.1 
IL-8                    385 ± 15                             265 ± 14                66.6 ± 22            38.8 ± 2.8             41 ± 2.1 
GRO-α               502 ± 13                             479 ± 14                469 ± 27              462 ± 10             463 ± 20 
TGF-α                39.9 ± 5.4                          57.3 ± 1.5                69 ± 7.5               91 ± 1.1             117 ± 6.6 
 
TABLE 14.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  TNF-α/IL-17 for 24 hours.  Data are expressed as means ± SD (n=3).  ND = 
not detected.  Stim = TNF-α (5ng/mL) + IL-17 (10ng/mL).  (*) n=2  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                              ND                        ND                        ND                  5.2 ± 1.9 
IL-8              86.5 ± 10.4                 5.1 ± 1.7*               6.9 ± 5.2                7.7 ± 5.3*          11.9 ± 5.4    
GRO-α               212 ± 13.3                  219 ± 15                243 ± 9.2               284 ± 22             308 ± 11 
TGF-α                43.2 ± 1.5                   47 ± 1.2*             73.7 ± 21.3             73.7 ± 8.4*          121 ± 35 
 
 
Cytokine           TNF-α (5ng/mL)                          SS (μg/mL) + Stim  
                          IL-17 (10ng/mL)                 12.5                         25                    50                      100 
 
IL-6                     34.8 ± 3.6*                     12.2 ± 9.4*             15.7 ± 2.8             16.3 ± 2.5*         20.5 ± 5.4 
IL-8    499 ± 40*                       352 ± 103*             398 ± 36               191 ± 37*            80 ± 9.6 
GRO-α                  600 ± 9.8                        554 ± 42                 554 ± 25               575 ± 35             517 ± 15 
TGF-α                  81.5 ± 20.1*                    48 ± 31*                 119 ± 33               134 ± 13*           235 ± 55 
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Figures 30 and 31.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on IL-8 expression 
from normal human epidermal keratinocytes.   Data are expressed as means ± SD (n=3).  Fig. 30.  *p< 0.05 
for SS compared to control, #p< 0.001 for SS and TNF-α/IL-17 compared to TNF-α/IL-17, ##p< 0.0001 for 
SS and TNF-α/IL-17 compared to TNF-α/IL-17, δp< 0.0002 for SS at 25μg/mL and TNF-α/IL-17 
compared to SS at 12.5μg/mL and TNF-α/IL-17, δδp< 0.0001 for SS at 50 and 100μg/mL and TNF-α/IL-17 
compared to SS at 12.5μg/mL and TNF-α/IL-17.  Fig. 31.  *p< 0.05 for SS compared to control, #p< 0.005 
for SS and TNF-α/IL-17 compared to TNF-α/IL-17, δp< 0.005 for SS at 50μg/mL and TNF-α/IL-17 
compared to SS at 25μg/mL and TNF-α/IL-17, δδp< 0.001 for SS at 100μg/mL and TNF-α/IL-17 compared 
to SS at 25μg/mL and TNF-α/IL-17.   
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Figures 32 and 33.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on GRO-α 
expression from normal human epidermal keratinocytes.   Data are expressed as means ± SD (n=3).  Fig. 
32.  *p< 0.05 for SS compared to control, **p< 0.005 for SS compared to control, #p< 0.05 for SS and 
TNF-α/IL-17 compared to TNF-α/IL-17  Fig. 33.  *p< 0.05 for SS compared to control, #p< 0.05 for SS 
and TNF-α/IL-17 compared to TNF-α/IL-17.   
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Figures 34 and 35.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on TGF-α expression 
from normal human epidermal keratinocytes.   Data are expressed as means ± SD (n=3).  Fig. 34.  *p< 
0.005 for SS compared to control, **p< 0.001 for SS compared to control, #p< 0.05 for SS and TNF-α/IL-
17 compared to TNF-α/IL-17, ##p< 0.005 for SS and TNF-α/IL-17 compared to TNF-α/IL-17.  Fig. 35.  
*p< 0.05 for SS compared to control, #p< 0.05 for SS and TNF-α/IL-17 compared to TNF-α/IL-17.   
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TABLE 15.  Cytokine production (pg/mL) from NHDF challenged with SS extract ±  
TNF-α/IL-17 for 8 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  
Stim = TNF-α (5ng/mL) + IL-17 (10ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                       72.9 ± 12.2            117 ± 16.4              138 ± 20               155 ± 23 
IL-8              20.8 ± 5.3                   134 ± 5.7              130 ± 6.6              70.8 ± 1.4              26.2 ± 7.5 
G-CSF                    ND                             ND                        ND                        ND                       ND 
GM-CSF                 ND                             ND                        ND                        ND                       ND    
 
 
Cytokine           TNF-α (5ng/mL)                 SS (μg/mL) + Stim  
                          IL-17 (10ng/mL)          12.5                        25              50                      100 
  
IL-6                      330 ± 2.2                347 ± 18.4              353 ± 16               343 ± 2.3             339 ± 4 
IL-8                        251 ± 18                 252 ± 13.7             302 ± 22.2             230 ± 16             241 ± 35 
G-CSF                    261 ± 48                  324 ± 45               390 ± 117              247 ± 11             229 ± 78 
GM-CSF               141 ± 11.3               74.7 ± 5.1               68.6 ± 6                30.9 ± 1.2            24.3 ± 13 
 
TABLE 16.  Cytokine production (pg/mL) from NHDF challenged with SS extract ±  
TNF-α/IL-17 for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = TNF-α (5ng/mL) + IL-17 (10ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                         339 ± 44                406 ± 6.5               418 ± 19.3             396 ± 10 
IL-8              35.4 ± 4.3                    237 ± 25                229 ± 1.4               258 ± 28                219 ± 9 
G-CSF                    ND                         377 ± 76                572 ± 58                789 ± 180              532 ± 104 
GM-CSF                 ND                        23.2 ± 3.2              16.1 ± 3.3              18.8 ± 2.1              5.9 ± 1.2    
 
 
Cytokine           TNF-α (5ng/mL)                SS (μg/mL) + Stim  
                          IL-17 (10ng/mL)         12.5                         25             50                       100 
  
IL-6                     436 ± 16                 440 ± 12                 442 ± 10               461 ± 19              418 ± 14 
IL-8                      269 ± 27                 265 ± 20                 244 ± 7.7              254 ± 27              224 ± 1.8 
G-CSF                 1092 ± 17              1108 ± 58               1077 ± 27             1051 ± 113            897 ± 33    
GM-CSF              500 ± 62                   285 ± 7                  245 ± 27              161 ± 6.4              106 ± 2   
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Figures 36 and 37.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on IL-6 
expression from normal human dermal fibroblasts.  Data are expressed as means ± SD (n=3).  
Fig. 36.  *p< 0.005 for SS compared to control.  Fig. 37.  *p< 0.001 for SS compared to control.   
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Figures 38 and 39.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on IL-8 
expression from normal human dermal fibroblasts.  Data are expressed as means ± SD (n=3).  
Fig. 38.  *p< 0.005 for SS compared to control, **p< 0.001 for SS compared to control, δp< 
0.005 for SS at 50μg/mL and TNF-α/IL-17 compared to SS at 12.5μg/mL and TNF-α/IL-17, δδp< 
0.001 for SS at 100μg/mL and TNF-α/IL-17 compared to SS at 12.5μg/mL and TNF-α/IL-17.   
Fig. 39.  *p< 0.005 for SS compared to control.  
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Figures 40 and 41.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on G-CSF 
expression from normal human dermal fibroblasts.  Data are expressed as means ± SD (n=3).    
Fig. 41.  *p< 0.005 for SS compared to control. 
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Figures 42 and 43.  Effect of S. scabiei var. canis extract along with TNF-α and IL-17 on GM-CSF 
expression from normal human dermal fibroblasts.  Data are expressed as means ± SD (n=3).  Fig. 42.  #p< 
0.001 for SS and TNF-α/IL-17 compared to TNF-α/IL-17, ##p< 0.0005 for SS and TNF-α/IL-17 compared 
to TNF-α/IL-17, δp< 0.0005 for SS at 50μg/mL and TNF-α/IL-17 compared to SS at 12.5μg/mL and TNF-
α/IL-17, δδp< 0.005 for SS at 100μg/mL and TNF-α/IL-17 compared to SS at 12.5μg/mL and TNF-α/IL-
17.   Fig. 43.  *p< 0.05 for SS compared to control, #p< 0.005 for SS and TNF-α/IL-17 compared to TNF-
α/IL-17, ##p< 0.001 for SS and TNF-α/IL-17 compared to TNF-α/IL-17, ###p< 0.0005 for SS and TNF-
α/IL-17 compared to TNF-α/IL-17, δp< 0.005 for SS at 50μg/mL and TNF-α/IL-17 compared to SS at 
12.5μg/mL and TNF-α/IL-17, δδp< 0.0005 for SS at 100μg/mL and TNF-α/IL-17 compared to SS at 
12.5μg/mL and TNF-α/IL-17.   
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Human skin cells challenged with S. scabiei var. canis extract ± IL-1α or IL-1β 
Preliminary Study 
 A dose response study to determine the optimum dosage of IL-1α and/or IL-1β to 
stimulate human skin cells for production of IL-6 and IL-8 showed that either IL-1α or 
IL-1β individually induced a dose-dependent up-regulation of IL-8 secretion from 
keratinocytes (Table 17, Fig. 44).  In addition, IL-6 was not expressed at the constititive 
level or IL-1α/IL-1β-induced level from keratinocytes.  Fibroblasts stimulated with 
varying doses of IL-1α or IL-1β expressed an increase in IL-6 and IL-8 expression levels 
above constitutive, however these levels represented the maximum expression levels of 
these cytokines and no differentiation could be made with the varying doses of IL-1α or 
IL-1β. 
NHEK-Adult 
IL-6 
 Cultured keratinocytes did not constitutively express IL-6 at 8 or 24 hours (Tables 
18-21).  Stimulation with SS extract, IL-1α/β, or SS and IL-1α/β did not induce IL-6 
expression from keratinocytes.   
IL-8 
 Keratinocytes constitutively expressed IL-8 at 8 and 24 hours (Tables 18-21, Figs. 
45-48).  Stimulation with varying doses of SS extract induced a slight but significant (p< 
0.05) down-regulation of IL-8 secretion from keratinocytes at 8 and 24 hours.  
Keratinocytes stimulated with IL-1α at 1ng/mL expressed increased secretion of IL-8 
above constitutive expression for 8 and 24 hours by 5- and 3.5-fold, respectively.  
Keratinocytes stimulated with IL-1β at 1ng/mL showed similar results for 8 and 24 hours 
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with increases of IL-8 by 4.5- and 4.3-fold, respectively.  Co-stimulation with varying 
doses of SS extract and either IL-1α or IL-1β induced a dose-dependent down-regulation 
of IL-8 observed at both 8 and 24 hours.   
GRO-α 
 Cultured keratinocytes constitutively expressed GRO-α at 8 and 24 hours (Tables 
18-21, Figs. 49-52).  Keratinocytes stimulated with SS extract at varying doses increased 
GRO-α expression above constitutive levels at both 8 and 24 hours.  Keratinocytes 
stimulated with IL-1α significantly (p< 0.05) increased expression of GRO-α at 8 and 24 
hours by 6.4- and 3.0-fold, respectively.  Likewise, keratinocytes stimulated with IL-1β 
significantly (p< 0.05) increased expression of GRO-α at 8 and 24 hours by 8.5- and 3.6-
fold, respectively.  Keratinocytes stimulated with SS extract and either IL-1α or IL-1β did 
not show increased expression above IL-1α or IL-1β-induced levels due to maximum 
expression levels of GRO-α at 8 and 24 hours.   
TGF-α 
 Keratinocytes did not constitutively express TGF-α at 8 or 24 hours (Tables 18-
21).  Stimulation with SS extract, IL-1α/IL-1β, or SS and IL-1α/IL-1β did not increase 
TGF-α expression levels.   
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TABLE 17.  Cytokine production (pg/mL) from NHEK-Adult challenged with IL-1α 
± IL-1β for 24 hours. Data are expressed as means ± SD (n=3).  ND = not detected. 
 
 
                      Cytokines (pg/mL) 
                        IL-8                                               IL-6 
Media Control                                  101.1 ± 14.9                                          ND 
 
IL-1α (ng/mL)                
0.1                  99.1 ± 13.4                                           ND 
1.0                 321.8 ± 29.2                                          ND 
10                 589.4 ± 49.4                                 ND 
 
IL-1β (ng/mL)  
0.1                  196.6 ± 5.9                                            ND 
1.0     594 ± 41.1                                             ND 
10       601 ± 13                                              ND 
 
IL-1α (ng/mL)  
+ IL-1β (ng/mL) 
               0.1 + 0.1                             176 ± 13                                                ND      
0.1 + 1.0                                                           419 ± 25                                               ND 
0.1 + 10                                                           507 ± 7.6                                               ND 
1.0 + 0.1                                                           401 ± 26                                               ND  
1.0 + 1.0                                                          511 ± 10.3                                             ND 
1.0 + 10                                                           566 ± 2.2                                               ND 
10 + 0.1                                                            484 ± 24                                               ND 
10 + 1.0                                                            541 ± 26                                               ND 
10 + 10                                                             581 ± 35                                               ND 
 
 
 
 
 
 
 
 
81 
 
 
 
Figure 44.  Dose response of IL-1α or IL-1β on the expression of IL-8 from normal human 
epidermal keratinocytes.  Data are represented as means ± SD (n=3).   
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IL‐1a 1.0ng/mL + IL‐1b 10ng/mL
IL‐1a 10ng/mL + IL‐1b 0.1ng/mL
IL‐1a 10ng/mL + IL‐1b 1.0ng/mL
IL‐1a 10ng/mL + IL‐1b 10ng/mL
IL‐8 pg/mL
NHEK‐Adult challenged with IL‐1α ± IL‐1β for 24 hours
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TABLE 18.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  IL-1α for 8 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = IL-1α (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                            ND                         ND                        ND                       ND  
IL-8               30.8 ± 2.5                 14.8 ± 7.7              13.6 ± 5.4               10.7 ± 4.7            18.9 ± 9.2 
GRO-α                146 ± 9.0                  247 ± 32                283 ± 6.4                263 ± 16              491 ± 45        
TGF-α                    ND                            ND                          ND                        ND                       ND  
 
 
Cytokine              IL-1α                            SS (μg/mL) + Stim  
                          (1ng/mL)                     12.5                         25                         50                           100 
  
IL-6                       ND                            ND                       ND                         ND                          ND  
IL-8                    152 ± 8.9                 155 ± 4.4               38.2 ± 12.5             14 ± 1.9                  19.4 ± 5.8 
GRO-α               937 ± 54                  1293 ± 91              1186 ± 19             1122 ± 114               1139 ± 39 
TGF-α                    ND                            ND                        ND                         ND                          ND       
 
TABLE 19.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  IL-1α for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = IL-1α (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                            ND                         ND                       ND                        ND   
IL-8               55.5 ± 5.4                  46.8 ± 8.6              34.1 ± 14               15.2 ± 8.4                ND 
GRO-α                543 ± 19                    728 ± 74               856 ± 95                 920 ± 65             1083 ± 134 
TGF-α                    ND                            ND                         ND                        ND                        ND 
 
 
Cytokine              IL-1α                          SS (μg/mL) + Stim  
                          (1ng/mL)                     12.5                         25                         50                           100 
  
IL-6                      ND                            ND                        ND                         ND                          ND 
IL-8                    191 ± 54                  281 ± 65                  214 ± 29              75.2 ± 13.3             22.6 ± 14.4 
GRO-α             1651 ± 150               1851 ± 114             1688 ± 137            1499 ± 197            1475 ± 103 
TGF-α                   ND                            ND                        ND                          ND                          ND 
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TABLE 20.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  IL-1β for 8 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = IL-1β (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                         100 
 
IL-6                       ND                            ND                         ND                        ND                       ND  
IL-8               53.9 ± 24.9               22.9 ± 5.8               21.4 ± 4.1             22.4 ± 4.6              31 ± 12.4 
GRO-α              157.6 ± 10.2              307.4 ± 8              354.3 ± 20.8          459.7 ± 20.3         537.8 ± 64.3 
TGF-α                    ND                            ND                          ND                        ND                       ND  
 
 
Cytokine              IL-1β                            SS (μg/mL) + Stim  
                          (1ng/mL)                     12.5                         25                          50                           100 
  
IL-6                       ND                            ND                       ND                         ND                          ND  
IL-8                    243 ± 21                    260 ± 11              143 ± 3.6                35.3 ± 6.6               41 ± 3.3 
GRO-α              1339 ± 95                  1540 ± 88             1572 ± 42              1554 ± 47               1488 ± 33 
TGF-α                    ND                            ND                        ND                         ND                          ND       
 
TABLE 21.  Cytokine production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  IL-1β for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = IL-1β (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                            ND                         ND                       ND                        ND   
IL-8               67.8 ± 2.0                 88.3 ± 14.4             52 ± 17.4              16.2 ± 2.5             14.7 ± 4.1 
GRO-α                501 ± 26                   678 ± 96                713 ± 145              840 ± 101             885 ± 85 
TGF-α                    ND                            ND                         ND                        ND                        ND 
 
 
Cytokine              IL-1β                          SS (μg/mL) + Stim  
                          (1ng/mL)                     12.5                         25                         50                           100 
  
IL-6                      ND                            ND                        ND                         ND                          ND 
IL-8                    298 ± 28                    408 ± 89               379 ± 105              204 ± 42               43.4 ± 24.3 
GRO-α             1806 ± 329                1937 ± 135            2117 ± 167            1932 ± 175           1848 ± 367 
TGF-α                   ND                            ND                        ND                          ND                          ND 
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Figures 45 and 46.  Effect of S. scabiei var. canis extract and IL-1α on IL-8 expression from 
normal human epidermal keratinocytes.  Data are expressed as means ± SD (n=3).  Fig. 45.  *p< 
0.05 for SS compared to control, **p< 0.01 for SS compared to control, #p< 0.0005 for SS and 
IL-1α compared to IL-1α, ##p< 0.0001 for SS and IL-1α compared to IL-1α.  Fig. 46.  *p< 0.005 
for SS compared to control, #p< 0.05 for SS and IL-1α compared to IL-1α, ##p< 0.01 for SS and 
IL-1α compared to IL-1α.   
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Figures 47 and 48.  Effect of S. scabiei var. canis extract and IL-1β on IL-8 expression from 
normal human epidermal keratinocytes.  Data are expressed as means ± SD (n=3).  Fig. 47.  #p< 
0.05 for SS and IL-1β compared to IL-1β, ##p< 0.0005 for SS and IL-1β compared to IL-1β.  Fig. 
48.  *p< 0.005 for SS compared to control, #p< 0.05 for SS and IL-1β compared to IL-1β, ##p< 
0.01 for SS and IL-1β compared to IL-1β.   
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Figures 49 and 50.  Effect of S. scabiei var. canis extract and IL-1α on GRO-α expression from 
normal human epidermal keratinocytes.  Data are expressed as means ± SD (n=3).  Fig. 49.  *p< 
0.01 for SS compared to control, **p< 0.0005 for SS compared to control, #p< 0.05 for SS and 
IL-1α compared to IL-1α.  Fig. 50.  *p< 0.05 for SS compared to control, **p< 0.005 for SS 
compared to control.   
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Figures 51 and 52.  Effect of S. scabiei var. canis extract and IL-1β on GRO-α expression from 
normal human epidermal keratinocytes.  Data are expressed as means ± SD (n=3).  Fig. 51.  *p< 
0.0005 for SS compared to control,  Fig. 52. *p< 0.05 for SS compared to control.   
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NHDF 
IL-6 
 Fibroblasts did not constitutively express IL-6 at 8 or 24 hours (Tables 22-25, 
Figs. 53-56).  Stimulation with varying doses of SS extract for 8 hours induced 
fibroblasts to dose-dependently up-regulate IL-6 expression above constitutive levels.  
Fibroblasts stimulated for 24 hours with varying doses of SS extract also increases IL-6 
expression in a dose-dependant manner except for the highest doses of SS in which no 
distinction can be made.  Fibroblasts stimulated with either IL-1α or IL-1β at 8 and 24 
hours induces a significant (p< 0.05) increase in the amount of IL-6 expression.  Co-
stimulation of fibroblasts with either IL-1α or IL-1β and varying doses of SS extract does 
not result in increased IL-6 expression beyond IL-1α or IL-1β-induced expression.   
IL-8 
 Fibroblasts constitutively expressed only a small amount of IL-8 at 8 and 24 hours 
(Tables 22-25, Figs. 57-60).  Stimulation of fibroblasts with varying doses of SS extract  
increased IL-8 expression at 8 and 24 hours, however there is down-regulation at the 
highest SS extract dosage tested for 8 hours of exposure.  This down-regulation is not 
seen at 24 hours of exposure.  Stimulation of fibroblasts with IL-1α or IL-1β significantly 
(p< 0.05) increased IL-8 expression above constitutive levels.  Co-stimulation of 
fibroblasts with either IL-1α or IL-1β and varying doses of SS extract did not induce up-
regulation beyond IL-1α or IL-1β-induced levels suggesting a maximum output of IL-8 
from fibroblasts under these experimental conditions.   
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G-CSF 
 Cultured fibroblasts did not constitutively express G-CSF at 8 or 24 hours (Tables 
22-25, Figs. 61-64).  Fibroblasts stimulated with varying doses of SS extract up-regulated 
expression of G-CSF in a dose-dependent manner at both 8 and 24 hours.  Stimulation 
with either IL-1α or IL-1β induced a significant (p< 0.05) up-regulation of G-CSF at 8 
and 24 hours.  Co-stimulation of fibroblasts with either IL-1α or IL-1β and varying doses 
of SS extract did not induce an increase in G-CSF expression beyond the levels induced 
by IL-1α or IL-1β alone.   
GM-CSF 
 Fibroblasts did not constitutively express GM-CSF at 8 or 24 hours in culture 
(Tables 22-25, Figs. 65-68).  Stimulation of fibroblasts with varying doses of SS extract 
induced a slight (p<0.05) up-regulation in GM-CSF expression at 8 and 24 hours.  
Stimulation with either IL-1α or IL-1β significantly (p< 0.05) increased GM-CSF 
expression at both 8 and 24 hours.  Co-stimulation of fibroblasts with either IL-1α or IL-
1β and varying doses of SS extract down-regulated GM-CSF expression in a dose-
dependent manner below IL-1α or IL-1β-induced levels.   
 
 
 
 
 
 
 
90 
 
TABLE 22.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
IL-1α for 8 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  Stim = 
IL-1α (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                       94.3 ± 24.3            188 ± 31.8               321 ± 41              483 ± 32 
IL-8               4.8 ± 2.6                    217 ± 47                247 ± 29                 215 ± 39              127 ± 12     
G-CSF                    ND                       67 ± 12.5                129 ± 34                 207 ± 36              277 ± 5.5    
GM-CSF                 ND                            ND                    2.0 ± 0.8                 2.7 ± 2.7              7.3 ± 1.4 
 
 
Cytokine                 IL-1α                               SS (μg/mL) + Stim  
                             (1ng/mL)                  12.5                         25             50                       100 
  
IL-6                      697 ± 37                 713 ± 36                748 ± 29                703 ± 30             756 ± 37 
IL-8                       419 ± 10                  358 ± 14                373 ± 2                  387 ± 7               388 ± 2 
G-CSF                  1338 ± 55               1245 ± 47              1364 ± 32              1343 ± 56           1459 ± 115                
GM-CSF               228 ± 42                 3.3 ± 15.5              67.3 ± 11.8            51.3 ± 15.5          50.6 ± 5.9 
 
TABLE 23.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
IL-1α for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  Stim 
= IL-1α (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                        ND                     2813 ± 400             5091 ± 661           7170 ± 169           5648 ± 177 
IL-8              13.4 ± 11.8              4891 ± 312             5791 ± 152           7475 ± 538            5810 ± 575 
G-CSF                     ND                       672 ± 83               1292 ± 135           1708 ± 32              1675 ± 84   
GM-CSF                  ND                       29 ± 4.5                20.7 ± 7.7             14.3 ± 7.8             14.1 ± 3.6 
 
 
Cytokine                 IL-1α                                SS (μg/mL) + Stim  
                             (1ng/mL)                  12.5                         25             50                       100 
  
IL-6                     5700 ± 361            6735 ± 475             6397 ± 487          7634 ± 481           7149 ± 195 
IL-8                      7139 ± 69              7380 ± 436             6644 ± 334          7592 ± 236           7095 ± 120   
G-CSF                  1910 ± 132            2045 ± 20               2026 ± 63            1972 ± 108           2130 ± 106               
GM-CSF                 277 ± 7                 112 ± 44                  78 ± 29                  60 ± 20                59 ± 22 
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TABLE 24.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
IL-1β for 8 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  Stim = 
IL-1β (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                         94.7 ± 7.9               149 ± 7                 276 ± 18               400 ± 39     
IL-8               3.4 ± 0.8                     173 ± 15                186 ± 8.6              178 ± 14               80.4 ± 13.9 
G-CSF                    ND                         56.7 ± 5.1              118 ± 3.6              161 ± 13.5             228 ± 26 
GM-CSF                 ND                            ND                      4.7 ± 4.3                  ND                       ND  
 
 
Cytokine                 IL-1β                               SS (μg/mL) + Stim  
                             (1ng/mL)                   12.5                        25             50                       100 
  
IL-6                    613 ± 27                    686 ± 71                652 ± 19                679 ± 33              719 ± 45 
IL-8                     387 ± 38                    383 ± 24                388 ± 9.2               350 ± 31              381 ± 14   
G-CSF                1361 ± 43                  1455 ± 116            1423 ± 119            1508 ± 217          1545 ± 385 
GM-CSF            162 ± 10.3                  91.8 ± 9.5              78.2 ± 13.3           74.9 ± 11.8          61.4 ± 10.3 
 
TABLE 25.  Cytokine production (pg/mL) from NHDF challenged with SS extract ± 
IL-1β for 24 hours.  Data are expressed as means ± SD (n=3).  ND = not detected.  Stim 
= IL-1β (1ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                        100 
 
IL-6                       ND                       1589 ± 235            3445 ± 650           5797 ± 648          5128 ± 128 
IL-8                   ND                       3691 ± 488            4699 ± 482           6386 ± 310          5314 ± 273 
G-CSF                    ND                        460 ± 77               1138 ± 103           1514 ± 69             1591 ± 48 
GM-CSF                 ND                       18.6 ± 2.4              14.1 ± 4.2              6.4 ± 1.2              9.0 ± 1.4      
 
 
Cytokine                 IL-1β                               SS (μg/mL) + Stim  
                             (1ng/mL)                   12.5                        25             50                       100 
  
IL-6                   6015 ± 920               6378 ± 583           5820 ± 255            7206 ± 372           6799 ± 180 
IL-8                    7829 ± 761               7246 ± 104           6689 ± 220            7861 ± 540           6943 ± 260    
G-CSF                2129 ± 128               1983 ± 105            2143 ± 51              2300 ± 42            2417 ± 70 
GM-CSF             319 ± 16.6                 102 ± 22               80.5 ± 25               77.3 ± 25              58 ± 4.6 
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Figures 53 and 54.  Effect of S. scabiei var. canis extract and IL-1α on IL-6 expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 53.  *p< 
0.005 for SS compared to control, **p< 0.0005 for SS compared to control, ***p< 0.0001 for SS 
compared to control.  Fig. 54.  *p< 0.0005 for SS compared to control.   
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Figures 55 and 56.  Effect of S. scabiei var. canis extract and IL-1β on IL-6 expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 55.  *p< 
0.0005 for SS compared to control, **p< 0.00005 for SS compared to control, ***p< 0.00001 for 
SS compared to control.  Fig. 56.  *p< 0.0005 for SS compared to control.   
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Figures 57 and 58.  Effect of S. scabiei var. canis extract and IL-1α on IL-8 expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 57.  *p< 
0.002 for SS compared to control, **p< 0.0002 for SS compared to control, ***p< 0.001 for SS 
compared to control, ****p< 0.0005 for SS compared to control, δp< 0.05 for SS at 100μg/mL 
compared to SS at 25μg/mL.  Fig. 58.  *p< 0.0005 for SS compared to control.   
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Figures 59 and 60.  Effect of S. scabiei var. canis extract and IL-1β on IL-8 expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 59.  *p< 
0.0005 for SS compared to control, **p< 0.001 for SS compared to control, δp< 0.005 for SS at 
100μg/mL compared to SS at 25μg/mL.  Fig. 60.  *p< 0.0005 for SS compared to control. 
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Figures 61 and 62.  Effect of S. scabiei var. canis extract and IL-1α on G-CSF expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 61.  *p< 
0.005 for SS compared to control, **p< 0.001 for SS compared to control, ***p< 0.00001 for SS 
compared to control.  Fig. 62.  *p< 0.002 for SS compared to control, **p< 0.0005 for SS 
compared to control, ***p< 0.00001 for SS compared to control.   
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Figures 63 and 64.  Effect of S. scabiei var. canis extract and IL-1β on G-CSF expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 63.  *p< 
0.005 for SS compared to control, **p< 0.0005 for SS compared to control, ***p< 0.0002 for SS 
compared to control.  Fig. 64.  *p< 0.001 for SS compared to control, **p< 0.0001 for SS 
compared to control.   
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Figures 65 and 66.  Effect of S. scabiei var. canis extract and IL-1α on GM-CSF expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 65.  *p< 
0.005 for SS compared to control, #p< 0.005 for SS and IL-1α compared to IL-1α, ##p< 0.002 for 
SS and IL-1α compared to IL-1α.  Fig. 66.  *p< 0.05 for SS compared to control, #p< 0.005 for 
SS and IL-1α compared to IL-1α, ##p< 0.0005 for SS and IL-1α compared to IL-1α.   
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Figures 67 and 68.  Effect of S. scabiei var. canis extract and IL-1β on GM-CSF expression from 
normal human dermal fibroblasts at 8 and 24 hours.  Data are means ± SD (n=3).  Fig. 67.  #p< 
0.001 for SS and IL-1β compared to IL-1β, ##p< 0.0005 for SS and IL-1β compared to IL-1β.  
Fig. 68.  *p< 0.05 for SS compared to control, #p< 0.05 for SS and IL-1β compared to IL-1β, 
##p< 0.005 for SS and IL-1β compared to IL-1β.   
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CTACK expression from keratinocytes challenged with S. scabiei var. canis extract 
± TNF-α for 48 hours 
Preliminary Study 
 An investigation to determine whether CTACK is expressed from normal human 
epidermal keratinocytes stimulated with various pro-inflammatory cytokines ± Th2 
cytokines revealed that TNF-α (10ng/mL) induced keratinocytes to up-regulate CTACK 
expression at 48 hours by 6-fold above constitutive expression (Table 26, Fig. 69).  This 
increase in CTACK expression by TNF-α was more than keratinocytes stimulated with 
IL-1α, IL-1β, IL-4, or IL-13.  In addition, co-stimulation of keratinocytes with TNF-α and 
either IL-1α or IL-1β did not induce CTACK expression greater than TNF-α-induced 
levels.  Co-stimulation of keratinocytes with TNF-α and either IL-4 or IL-13 induced a 
down-regulatory effect on CTACK expression.   
CTACK 
 NHEK-Adult produced a small amount of constitutive CTACK expression at 48 
hours (Table 27, Fig. 70).  Stimulation with TNF-α at 10ng/mL induced an up-regulation 
of CTACK at 48 hours.  Stimulation with varying doses of SS extract induced an up-
regulation (p< 0.0005) of CTACK above constitutive levels.  Stimulation with SS extract 
at doses of 12.5, 25, and 50μg/mL + TNF-α induced a synergistic up-regulation of 
CTACK above TNF-α-induced levels, however SS at 100μg/mL + TNF-α did not show 
up-regulation of CTACK.   
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TABLE 26.  Cytokine production (pg/mL) from NHEK-Adult challenged with TNF-
α ± IL-1α, IL-1β, IL-4, or IL-13 for 48 hours. Data are expressed as means ± SD (n=3).  
ND = not detected. 
 
 
                   Cytokines (pg/mL) 
                               CTACK                                              TSLP         
Media Control                                 107 ± 43.8                                             ND 
TNF-α 10ng/mL                               604 ± 76                                               ND 
IL-1α 10ng/mL                                241 ± 116                                              ND 
IL-1β 10ng/mL                                 285 ± 44                                               ND 
IL-4 10ng/mL                                   233 ± 48                                               ND 
IL-13 10ng/mL                                 284 ± 65                                               ND 
TNF-α + IL-1α                                 778 ± 96                                               ND 
TNF-α + IL-1β                                 712 ± 150                                              ND 
TNF-α + IL-4                                   313 ± 79                                                ND          
TNF-α + IL-13                                 345 ± 70                                                ND 
 
 TABLE 27.  CTACK production (pg/mL) from NHEK-Adult challenged with SS 
extract ±  TNF-α for 48 hours.  Data are expressed as means ± SD (n=3).  ND = not 
detected.  Stim = TNF-α (10ng/mL).  
 
 
Cytokine  Media                                     SS (μg/mL) 
  Control          12.5            25            50                         100 
 
CTACK               144 ± 25                   580 ± 36                683 ± 28               576 ± 82               473 ± 46  
 
 
Cytokine              TNF-α                            SS (μg/mL) + Stim  
                          (10ng/mL)        12.5                         25                         50                         100 
  
CTACK              697 ± 96                  1256 ± 102             1533 ± 43            1075 ± 73               615 ± 96                                     
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Figure 69.  CTACK production from NHEK-Ad challenged with various pro-inflammatory 
cytokines for 48 hours.   
 
 
 
Figure 70.  Effect of TNF-α and SS extract on CTACK expression from NHEK-Ad at 48 hours.  
Data are means ± SD (n=3).  *p< 0.0005 for SS compared to control, #p< 0.005 for SS and TNF-
α compared to TNF-α, ##p< 0.0005 for SS and TNF-α compared to TNF-α, ###p< 0.01 for SS 
and TNF-α compared to TNF-α. 
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Epidermal keratinocytes challenged with TNF-α, Cystatin A, and/or SS extract for 8 
hours 
 Stimulation of NHEK-Adult with TNF-α (5ng/mL) induced an up-regulation of 
IL-8 at 8 hours (Data not shown).  Stimulation with Cystatin A did not up-regulate IL-8.  
Stimulation with TNF-α and Cystatin A induced similar IL-8 results seen for NHEK-Ad 
challenged with TNF-α.  Addition of SS extract (50 and 25μg/mL) with TNF-α and 
Cystatin A caused a down-regulation of IL-8 from NHEK-Ad as was seen with previous 
studies.    
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DISCUSSION 
 Sarcoptes scabiei is an obligate ectoparasite known to infest human and other 
mammalian skin (Arlian et al., 2003; Arlian et al., 2004b).  Residential skin cells 
including keratinocytes and fibroblasts that are exposed to burrowing mites and/or their 
metabolic products may change their secretion of cytokines and chemokines to the mites 
and this modulation may result in a delay of the initial immune/inflammatory response.  
The purpose of this research was to investigate whether components from an extract of 
Sarcoptes scabiei can modulate cytokine and chemokine expression from primary normal 
human keratinocytes and fibroblasts in vitro.              
In this study, S. scabiei extract induced increased expression of IL-6, GRO-α, 
TGF-α and CTACK from cultured human keratinocytes as well as IL-6 and G-CSF from 
cultured human fibroblasts.  In comparison, S. scabiei extract decreased expression of IL-
8 and IL-1ra from cultured human keratinocytes as well as IL-8 and GM-CSF from 
cultured human fibroblasts.  Neither keratinocytes nor fibroblasts expressed TARC or 
TSLP in this study upon exposure to the mite extract.   
It is difficult to understand how individual cytokine expression and modulation in 
vitro correlates with the complexity of cytokine interactions that occur during cutaneous 
inflammation and immunity in vivo.  Interpreting cytokine and chemokine functions can, 
however, provide necessary insights into potential mechanisms by which scabies mites 
and/or mite products modulate the immune/inflammatory response during initial 
infestation.  
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Interleukin-6 is a multifunctional cytokine that plays a key role in the 
immune/inflammatory response to threats from the environment.  IL-6 induces 
maturation of B- and T-cells (Turksen et al., 1992; Koch et al., 1992) into either 
immunoglobulin-secreting plasma cells or CD4+ TH-cells, respectively.  IL-6 also 
increases vascular permeability (Arlian et al., 2003) and mediates acute phase protein 
production by liver hepatocytes.  In this study, IL-6 expression by cultured keratinocytes 
was slightly up-regulated above constitutive levels from stimulation with scabies extract.  
In comparison, IL-6 expression from cultured fibroblasts was intensely up-regulated 
above constitutive expression from stimulation with scabies extract.  Since microvascular 
endothelial cells only slightly increase IL-6 expression from exposure to scabies extract 
(Arlian et al., 2006), these findings taken together suggest that fibroblasts, and not 
keratinocytes nor endothelial cells, are the primary residential cutaneous cell producers of 
IL-6 during exposure to scabies mites and/or their products.   
An additional cell type known to increase production of IL-6 upon exposure to 
scabies extract are monocytes (Arlian et al., 2004b).   Mononuclear cells, which consist 
of monocytes and lymphocytes, constitute a major dermal cellular infiltrate during both 
initial and challenge scabies infestations (Arlian et al., 1997; Arlian et al., 2004b).  
Therefore, an increase of IL-6 expression from fibroblasts and monocytes may induce a 
gradual increase in migration and activation of plasma cells into the dermis near scabietic 
lesions (Arlian et al., 2003; Arlian et al., 1994).  Increased infiltration of plasma cells into 
the dermis may result in increased scabies-specific circulating antibody titers.  This is 
consistent with an increase of scabies-specific immunoglobulin in serum obtained from 
infested hosts (Arlian et al., 1994; Arlian et al., 1995).  
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Interestingly, IL-6 also mediates many anti-inflammatory and immunoregulatory 
functions within cutaneous tissues.  Infiltration of peripheral blood mononuclear cells 
into the dermis near scabietic lesions, possibly enticed by increased IL-6 production, may 
contain type 1 T-regulatory cells.  In a previous study, scabies extract induced high-levels 
of IL-10 production from peripheral blood mononuclear cells (Arlian et al., 2006a).  It 
was suggested that this IL-10 production was from T-regulatory cells rather than TH2-
type cells because of a lack of IL-4 production (Arlian et al., 2006a).  Interleukin-10 
exhibits many anti-inflammatory and immunosuppressive effects; therefore, T-regulatory 
cells induced by IL-6 may act to suppress the early immune/inflammatory response seen 
during initial scabies infestation.  Further investigation is needed to determine whether T-
regulatory cells comprise a subpopulation of T-cells near the scabietic lesion in vivo. 
The physical barrier of skin may also determine when dermal fibroblasts actually 
become exposed to either scabies mites and/or mite products.  Infesting mites reside just 
above the squamous cell layer of the epidermis (Arlian et al., 1996) near the dermal-
epidermal junction and rarely burrow beyond the basal cell layer of the epidermis.  
Therefore, it is possible that a delay in initial exposure of fibroblasts to scabies mites 
and/or mite products impedes IL-6 production from fibroblasts.  This may partially 
account for the 4-6 week delay before the onset of symptoms associated with initial 
scabies infestation.     
Scabies mites may also mediate IL-6 production from dermal fibroblasts through 
the modulation of keratinocyte-derived IL-1α.  Fibroblasts stimulated with IL-1α 
significantly up-regulate IL-6 production, however a previous study (Arlian et al., 2003) 
has shown that monocultures of keratinocytes exposed to S. scabiei extract in vitro does 
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not up-regulate IL-1α expression.  These results differ from a previous study (Arlian et 
al., 1996) where it was shown that live scabies mites which infested human skin 
equivalents (HSEs) increased production of IL-1α and IL-1β.  Whether IL-1 modulation 
from keratinocytes influences IL-6 production from fibroblasts during scabies infestation 
is uncertain, but this may provide one of several different pathways through which 
scabies modulates and evades the initial immune/inflammatory response of the host.           
A histopathological feature of severe scabies infestation is hyperkeratosis of the 
epidermis and stratum corneum layers (Arlian et al., 2003).  Results from this study have 
shown that in addition to IL-6 production from fibroblasts, TGF-α is dose-dependently 
up-regulated from keratinocytes exposed to S. scabiei extract.  Transforming growth 
factor-α is a growth and differentiation cytokine commonly found during wound healing 
and in psoriasis of the skin (Miller et al., 2005).  In addition, TGF-α can increase 
expression of TLRs found on the surface of epidermal keratinocytes (Miller et al., 2005).  
Taken together, both IL-6 and TGF-α up-regulation may contribute to rapid keratinocyte 
proliferation (hyperkeratosis) symptomatic of chronic scabies infestation.   
The recruitment of leukocytes and lymphocytes to areas of tissue injury and 
inflammation is essential to mount effective innate and adaptive immune responses.  
Within skin, the recruitment of neutrophils is accomplished primarily through expression 
of the chemokines interleukin-8 (Arlian et al., 2003) and growth-related oncogene-alpha.  
Neutrophils have a significant role in the immune/inflammatory response through both 
phagocytosis of foreign antigen as well as through degranulation of organelles containing 
vasodilators and various inflammatory mediators.  In addition, activated neutrophils are 
induced to release various oxygen free radicals collectively known as the oxidative burst.  
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The release of these reactive oxygen species into the extracellular environment of 
cutaneous tissues induces cellular activation and up-regulation of various pro-
inflammatory cytokines and cytokine receptors.  Although unconfirmed, the release of 
reactive oxygen species may also interfere with burrowing mites and/or mite products 
through oxidation of various proteins and lipids either secreted from the mite or located 
on the mite body.  It should also be noted that although reactive oxygen intermediates 
may induce inflammation and immune responses in skin, uncontrolled excessive release 
of oxide free radicals by neutrophils can cause severe tissue damage and destruction.  
This means that a very delicate balance must exist for neutrophil recruitment towards site 
specific locations within skin.      
This study found that keratinocytes do not constitutively produce IL-8 in vitro; 
however IL-8 production could be induced from keratinocytes stimulated with various 
pro-inflammatory cytokines.  In agreement with previous research (Arlian et al., 2003); 
scabies extract dose-dependently down-regulated expression of IL-8 from TNF-α, TNF-
α/IL-17, IL-1α, and IL-1β-stimulated keratinocytes.  To further investigate the IL-8 
down-regulating capability of scabies extract, cultured human keratinocytes were 
stimulated with TNF-α and either scabies extract supernatant or scabies extract re-
suspended pellet obtained from centrifuged whole-body scabies extract.  Keratinocytes 
stimulated with scabies extract supernatant dose-dependently up-regulated IL-8 
expression above TNF-α-induced levels, while stimulation with scabies extract re-
suspended pellet inhibited increased IL-8 expression at the highest dosage assayed.  
These results suggest that an IL-8 suppressor found in the pellet of centrifuged re-
suspended scabies extract may be inhibiting local recruitment and transendothelial 
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migration of neutrophils to areas of scabies infestation in vivo.  Since neutrophils are one 
of the earliest immune cell responders to cutaneous stimuli, the postponement of early 
neutrophil recruitment in skin could contribute to the initial delay of symptoms associated 
with primary scabies infestation.        
Interleukin-8 is also known to be produced by dermal fibroblasts, microvascular 
endothelial cells, dermal dendritic cells, and mononuclear cells in vitro.  Previous 
research has indicated that IL-8 is constitutively produced by microvascular endothelial 
cells (Arlian et al., 2006b) and dermal dendritic cells (Arlian et al., 2004b) and that 
exposure to scabies extract dose-dependently down-regulates IL-8 expression.  In 
addition, IL-8 is constitutively produced by peripheral blood mononuclear cells and 
exposure to scabies extract induces up-regulation of IL-8 expression (Arlian et al., 
2004b).  In this study, IL-8 was also constitutively produced from dermal fibroblasts 
suggesting that various dermal cell types participate in recruiting neutrophils within the 
skin periphery to monitor for threats from various pathogens.  Binding of IL-8 to either 
CXCR-1 or CXCR-2 on endothelial cells induces increased affinity between neutrophil 
intergrin receptors and endothelial cell surface adhesion molecules (Arlian et al., 2006b) 
resulting in extravasation of neutrophils into skin.  Thus, down-regulated IL-8 expression 
from fibroblasts, dermal dendritic cells, and microvascular endothelial cells could 
contribute to the 4-6 week delay of symptoms upon initial scabies infestation.     
An interesting find from this study was that both the dose of scabies extract and 
the duration of exposure to scabies extract affected the secretion of IL-8 from cultured 
fibroblasts.  Fibroblasts exposed to low doses of scabies extract (12.5 or 25μg/mL) for 
shorter time periods (8 or 12 hours) increased IL-8 expression.  However, fibroblasts 
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exposed to high doses of scabies extract (50 or 100μg/mL) for shorter time periods (8 or 
12 hours) down-regulated IL-8 expression. In addition, fibroblasts exposed to scabies 
extract for 24 hours maintained increased expression of IL-8, similar to previous results 
(Arlian et al., 2003).  This is the first report to indicate that scabies extract can down-
regulate IL-8 expression from dermal fibroblasts in vitro.  Based on these results, scabies 
mites may act to suppress IL-8 expression from fibroblasts long enough to establish 
infestation within the stratum corneum layer of skin prior to neutrophil recruitment.  This 
could add to the delay of symptoms with initial scabies infestation.    
Another potent neutrophil chemoattractant expressed from keratinocytes is growth 
related oncogene-α.  Similar to IL-8, GRO-α recruits mainly neutrophils and some T-
lymphocytes to areas of tissue injury and inflammation.  In this study, cultured 
keratinocytes constitutively expressed GRO-α and exposure to scabies extract dose-
dependently up-regulated GRO-α expression.  Since IL-8 was down-regulated from 
fibroblasts exposed to low doses of scabies extract for short time periods, it is difficult to 
understand why two neutrophil chemotactic factors would be differentially expressed 
under these conditions.  One possibility is that IL-8 is more potent for neutrophil 
chemoattraction; therefore modulation of IL-8 provides a better means for immune 
evasiveness by scabies.  Another possibility is that both IL-8 and GRO-α work together 
to bring about neutrophil recruitment to skin tissue, therefore down-regulating IL-8 
temporarily suppresses neutrophil immigration.  Interestingly, IL-8 can bind to both 
CXCR-1 and CXCR-2 found on the surface of endothelial cells, while GRO-α is specific 
for binding to CXCR-2.  In a previous study, microvascular endothelial cells exposed to 
scabies extract down-regulated expression of CXCR-2 but not CXCR-1 (Arlian et al., 
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2004b).  Therefore, down-regulation of the GRO-α receptor by scabies mites and/or mite 
products may inhibit endothelial cell-neutrophil binding resulting in a delay before 
transendothelial migration of neutrophils into the skin periphery.  The method(s) by 
which scabies suppresses the initial immune/inflammatory response are not well 
understood, however a lack of neutrophil infiltration would contribute in a 4-6 week 
delay before cutaneous symptoms are observed.       
Haematopoietic colony-stimulating factors such as G-CSF and GM-CSF are 
important in the growth and differentiation of various leukocytes and lymphocytes 
throughout the body.  While G-CSF is lineage specific inducing formation of granulocyte 
colonies and regulating granulopoiesis, GM-CSF is a multilineage cytokine responsible 
for stimulating formation of neutrophils, eosinophils, and macrophages.  In this study, 
normal human dermal fibroblasts were investigated for expression and modulation of 
both G-CSF and GM-CSF upon exposure to scabies extract.  This study found that 
fibroblasts did not constitutively express G-CSF or GM-CSF in vitro; however, 
stimulation with either TNF-α and IL-17, IL-1α, or IL-1β induced expression of both 
growth factors.  Fibroblasts stimulated with scabies extract increased G-CSF expression 
in a dose-dependent fashion; however co-stimulation of fibroblasts with scabies extract 
and pro-inflammatory cytokines did not show increased G-CSF expression.  The receptor 
for G-CSF has been found on activated neutrophils (Cosman, 1988) suggesting that 
scabies mites and/or mite products may contribute towards neutrophil activation.  Since it 
is beneficial for the survival of the mites to inhibit neutrophil recruitment and activation 
with skin, it is uncertain why G-CSF is up-regulated from fibroblasts upon exposure to 
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scabies extract.  Further investigation is required to understand G-CSF modulation from 
dermal fibroblasts upon exposure to scabies mites and/or mite products.   
The cytokine GM-CSF has also been shown to be produced by dermal fibroblasts.     
However, since fibroblasts in this study were unable to constitutively express GM-CSF in 
vitro, these cells were induced to express GM-CSF by exposing them to various pro-
inflammatory cytokines including both TNF-α and IL-17, IL-1α, or IL-1β.  Co-
stimulation of fibroblasts with pro-inflammatory cytokines and scabies extract revealed 
that scabies extract dose-dependently down-regulated expression of GM-CSF from 
fibroblasts in vitro that was induced by the pro-inflammatory cytokines alone.  GM-CSF 
promotes growth and differentiation of not only granulocytes, but also monocytes and 
macrophages (including epidermal Langerhans cells).  Therefore, these results suggest 
that scabies mites and/or mite products can modulate GM-CSF production from 
fibroblasts during infestation.  If this occurs, granulocytes (mostly neutrophils) may be 
impaired in their ability to become activated to scabies mites and/or mite products.  
Taken together with the possibility of IL-8 suppression, down-regulated GM-CSF may 
provide the mite(s) with a mechanism to evade the host’s initial immune and 
inflammatory response.       
The chemokine CTACK, or CCL27, mediates skin homing of CLA+ T-
lymphocytes and is produced exclusively by epidermal keratinocytes (Kanda et al., 
2005).  Although typically seen in patients suffering from atopic dermatitis (Nomura et 
al., 2003), CTACK may be produced by keratinocytes in response to scabies infestation.  
This study found that CTACK is constitutively produced by keratinocytes, however only 
after the cells have been in culture for at least 48 hours.  Stimulation of cultured 
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keratinocytes with either scabies extract or TNF-α induced marked increase in CTACK 
expression at 48 hours of exposure.  Co-stimulation of keratinocytes with scabies extract 
and TNF-α increased CTACK expression suggesting that these two stimuli induce 
CTACK through different signal-transduction pathways.  Interestingly, co-stimulation of 
keratinocytes with TNF-α and scabies extract at 100μg/mL induced down-regulation of 
CTACK expression.  These results suggest that having few scabies mites on a host (as 
seen during initial infestation) may elicit recruitment of T-cells towards the skin 
periphery through expression of CTACK from keratinocytes.  However, as the scabies 
mite populations increase, an ability to effectively recruit and activate T-cells may be 
inhibited.  These results may provide information pertaining to the early infiltration of T-
cells near scabietic lesions as observed during histological analysis (Arlian et al., 2004a).    
In conclusion, this study suggests that both keratinocytes and fibroblasts have 
significant roles in the immune/inflammatory response to scabies infestation.  Whether 
results from this study obtained in vitro mimics the human skin cell response in vivo to 
scabies is unclear, however this study does provide useful insight into understanding the 
complex nature of this host-parasite interaction.  Further investigations into cytokine and 
chemokine modulation from residential skin cells and circulating immune cells should 
contribute to the understanding of how scabies delays the initial host inflammatory and 
immune response.     
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APPENDIX 
 
LIST OF ABBREVIATIONS & ACRONYMS 
 
NHEK ………………………Normal Human Epidermal Keratinocyte 
 
NHDF……………………….Normal Human Dermal Fibroblast 
 
HMVEC-D………………….Human Microvascular Endothelial Cell 
 
IL-1α………………………..Interleukin 1-alpha 
 
IL-1β………………………..Interleukin 1-beta 
 
IL-1ra……………………….Interleukin 1-receptor antagonist 
 
TNF-α………………………Tumor Necrosis Factor-alpha 
 
IL-6………………………….Interleukin-6 
 
IL-8………………………….Interleukin-8 
 
GM-CSF…………………….Granulocyte  macrophage-colony stimulating factor 
 
IL-10………………………...Interleukin-10 
 
TGF-α……………………….Transforming growth factor-alpha 
 
PDGF………………………..Platelet-derived growth factor 
 
IL-15………………………...Interleukin-15 
 
TH1/TH2……………………..T helper 1/T helper 2 cells 
 
SS……………………………Sarcoptes scabiei 
 
VCAM-1…………………….Vascular cell adhesion molecule-1 
 
CXCR-1……………………..Chemokine receptor-1 
 
IL-4………………………….Interleukin-4 
 
IL-10………………………...Interleukin-10 
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LIST OF ABBREVIATIONS & ACRONYMS CONTINUED 
 
IFN-γ………………………..Interferon-gamma 
 
HSE…………………………Human skin equivalent 
 
TREG…………………………T-regulatory cell 
 
VEGF………………………..Vascular endothelial growth factor 
 
TLR………………………….Toll-like receptor 
 
Der p 1……………………….Dermatophagoides pteronyssinus 1 
 
Der f 1……………………….Dermatophagoides farinae 1 
 
IL-6sR……………………….Interleukin-6 soluble receptor 
 
IL-17…………………………Interleukin-17 
 
MCP-1……………………….Monocyte chemoattractant protein-1 
 
GRO-α, β, γ………………….Growth related oncogene-alpha, beta, gamma 
 
IL-7…………………………..Interleukin-7 
 
IL-15…………………………Interleukin-15 
 
IL-16…………………………Interleukin-16 
 
IP-10…………………………Inducing protein-10 
 
G-CSF……………………….Granulocyte-colony stimulating factor 
 
KGF………………………….Keratinocyte growth factor 
 
SMIPPs………………………Scabies mite inactivated protease paralogues 
 
CLA………………………….Cutaneous lymphocyte antigen 
 
CCL……………………..…...Chemokine ligand 
 
CCR10……………………….Chemokine receptor 10 
 
CCR4………………………...Chemokine receptor 4 
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LIST OF ABBREVIATIONS & ACRONYMS CONTINUED 
 
TARC………………………...Thymus and activation -regulated chemokine 
 
CTACK………………………Cutaneous T-cell attracting chemokine 
 
TSLP…………………………Thymic stromal lymphopoietin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
